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ABSTRACT 
 Genetic testing is becoming increasingly important to medical practice since the 
completion of the Human Genome project. To realize the full promise of personalized 
medicine, we need to first integrate genetic and genomic information into Electronic 
Health Records (EHRs) as coded and structured data using standards. However, EHRs 
are not ready for genomic medicine; lack of standardized information models and termi-
nologies for genetic and genomic data representation is recognized as one of the major 
barriers.  
In this study, we have focused on constitutional cytogenetic tests. We first evaluat-
ed the Logical Observation Identifiers Names and Codes (LOINC), the de facto vocabu-
lary standard for representing laboratory test names and results, and identified that a gap 
exists in LOINC to support the integration of cytogenetic test results into EHRs. We ana-
lyzed sample clinical reports from several large cytogenetics laboratories, and developed 
LOINC panels and codes for representing constitutional cytogenetic test findings through 
the LOINC panel approach. The LOINC committee approved the cytogenetic LOINC 
panels and officially released them as part of the LOINC database in December 2010. We 
then followed the well vetted standard development process of Health Level Seven 
(HL7), developed and balloted a HL7 version 2 implementation guide that details how 
these LOINC panels are coupled with the messaging standard to transfer cytogenetic test 
    
iv 
results over the wire. We also described the advantages of coupling the LOINC panel 
content to HL7 version 2 messages, and why we think this approach could be a practical 
and efficient way for implementers to develop interfaces that utilize standard information 
models bound to standard terminologies. 
We have filled the gap that there were no standard information models and no 
standard terminologies for representing constitutional cytogenetic test results, and have 
developed the foundation to allow incremental enhancement in the future.  
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The successful completion of the Human Genome Project in April 2003 marked 
the beginning of the “genome era.” One of the great impacts that genomics has on im-
proved patient care is its applications to diagnostics. The number of disease tests has in-
creased from 110 to over 2,400 in the past 20 years or so; about 2,200 of them are for 
clinical use [1]. Tests that were uncommon a short while ago are now routinely per-
formed at genetic testing labs all over the United States.  Patients are being exposed to 
greater amounts of genetic information routinely. For example, newborn screening is be-
ing expanded to test for over 30 diseases depending on the state [2]. The global molecular 
diagnostics market was worth $6.5 billion in 2005; it will expand to $35 billion by 2015 
[3]. Genetic/genomic data are becoming increasingly important for clinical decision mak-
ing. Translating the knowledge from genetic/genomic discoveries into practical clinical 
applications is critical for realizing the potential of personalized health care and improv-
ing the health of the nation.  
Statement of the Problem 
With genetic testing as a part of mainstream medicine, not only will clinical pro-
fessionals be expected to become more genetically literate, but also the clinical infor-




exchange of genetic and genomic information. Currently, genetic test results exist as nar-
rative reports; they are not integrated with the Electronic Health Records (EHRs) in most 
institutions. It is well recognized within the genetic testing field that standards are lacking 
in many aspects of the process of ordering, results reporting, and interpretation of genetic 
tests [4]. The format of genetic test requisitions and result reports varies from laboratory 
to laboratory; test results lack clarity about the clinical significance of the findings and 
are not clinician friendly. All of these pose huge communication issues among profes-
sionals in both laboratory and clinical settings, and could potentially lead to substandard 
quality control, misdiagnoses, poor healthcare decision-making or counseling and there-
fore a less desirable patient outcome.   
Most traditional clinical information systems are not designed with incorporating 
genetic and genomic information in mind. Lack of standards for data elements, terminol-
ogy, structure, interoperability, and clinical decision support rules is one of the major bar-
riers and challenges to the integration of genetic/genomic information with clinical data 
[5].  
Standard terminologies alone are not sufficient to unambiguously exchange data 
between heterogeneous systems, to share decision support logic, or to support the sec-
ondary use of clinical data. Information models, which provide semantic structure of the 
data representation and specify how vocabulary should be bound to each slot of the se-
mantic structure, are crucial for achieving interoperability. Information models that are 
tightly coupled with standard terminologies put discrete data elements into meaningful 
Objectives 
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context, which can then be shared consistently across systems and institutions. Together, 
standardized terminologies and information models are one of the fundamental building 
blocks for realizing semantic interoperability.  
This study has two specific aims as outlined below:  
Aim 1: Develop information models to represent the semantics of constitutional 
cytogenetic test results, and use the models to guide the creation of LOINC codes to rep-
resent the test results. This aim is not to try to develop a list of standard terminologies 
and information models that are comprehensive, but rather to focus on developing termi-
nologies and information models that are flexible and sustainable.  
Aim 2: Develop a standard implementation guide for messaging cytogenetic test 
results, which uses the information models and the LOINC codes as the interoperability 
building blocks, and follows the well vetted standard development process of Health 
Level Seven (HL7). The implementation guide specifies how cytogenetic test results 
should be transmitted over the wire. It not only fits the rapid changing and evolving na-
ture of the field of genetic testing but also is able to take advantage of the existing EHR 
infrastructure that could lead to rapid adoption and implementation in the United States.  
1  GeneTests. GeneTests. http://www.ncbi.nlm.nih.gov/sites/GeneTests/ (accessed 24 
Feb2012). 
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CHAPTER 2 
BACKGROUND 
Genetic tests are greatly impacted by the exponential growth of genetic research 
discoveries and technological innovations. According to GeneTests, a genetic test is de-
fined as the analysis of human DNA, RNA, chromosomes, proteins, and certain metabo-
lites in order to detect a heritable disorder. This can be accomplished by directly examin-
ing the DNA and RNA that make up a gene (direct testing), looking at markers co-
inherited with a disease-causing gene (linkage testing), assaying certain metabolites (bio-
chemical testing), or examining the chromosomes (cytogenetic testing) [1]. It is also im-
portant to note that genetic tests are increasingly being applied to acquired somatic 
changes to cells, particularly in cancer, so the definition limiting testing to heritable dis-
orders is increasingly obsolete. This has been reflected in the definition adopted by the 
Genetic Testing Registry (GTR) [2]. The National Institutes of Health (NIH) established 
the GTR to serve as the single public resource to provide detailed information about the 
1600+ genetic tests for patients and consumers; NIH made the registry available to the 
public in early 2012. GTR defines a genetic test as the analysis of DNA, RNA, chromo-
somes, proteins, or metabolites to detect genotypes, mutations, chromosomal changes, or 
levels of gene expression in a human sample [2]. Because of the broad scope and fast 
Cytogenetic Tests 
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evolving nature of genetic testing, it is impractical to tackle standard information models 
and terminologies for all genetic tests at once. This dissertation research focuses on cyto-
genetic testing—one domain within the field of genetic testing. However, the goal is that 
we could easily generalize the approach we have used to develop the information models 
and standard terminologies for cytogenetic test results and apply that approach to other 
genetic testing domains.    
Cytogenetic tests evaluate whole chromosomes in the nucleus of the cell for 
changes in number or structure. Cytogenetic testing is used in various clinical situations. 
These historically included assessment of a developmentally delayed child, evaluation of 
a cancerous tumor, or prenatal studies to detect chromosomal anomalies in a fetus [3]. 
The emerging field of cytogenomics includes conventional cytogenetics, which uses 
chromosomal banding techniques, in addition to molecular technologies such as fluores-
cence in situ hybridization (FISH), and cytogenomic microarray (arr). FISH is often used 
in prenatal diagnosis when results are needed rapidly to detect chromosomal aneusomies 
such as Down syndrome (trisomy 21), and also to detect chromosomal deletions, duplica-
tions, or rearrangements that are not visible using microscopy [4]. Cytogenomic microar-
ray circumvents a limitation of FISH as it does not require foreknowledge of the chromo-
somal loci being evaluated [5].  
The introduction of arr to clinical cytogenetics has facilitated the genome-wide 
detection of DNA copy number imbalances at resolutions significantly higher than previ-
ously attainable [5]. Conventional and molecular cytogenetics technologies are often used 
to complement each other or used together in this evolving practice. 
7 
   
Cytogenetic Test Result Reporting 
Test names vary significantly between different genetic laboratories and this lack 
of consistency can be confusing.  Individuals unfamiliar with a specific cytogenetic test 
name may need to inquire directly with laboratory personnel. Standardizing the cytoge-
netic test names and representing them using universal identifiers would save unneces-
sary work, improve efficiency of communication, enhance data interoperability, prevent 
possible ordering mistakes, and ultimately improve patient care.  
Unlike other laboratory reports, the majority of genetic tests including cytogenetic 
tests are now reported as a narrative report. These narrative reports are sent through HL7 
version 2 (V2) messages and are stored as narrative text in EHRs. Genetic test results are 
integrated with other clinical data for full clinical assessment. The current narrative for-
mat traps the information in the language of the report, which makes it difficult to find a 
specific detail without reading through the report and difficult to enable computerized 
decision support. These narrative reports vary from laboratory to laboratory, which some-
times results in incomplete communication between testing laboratories and clinicians, 
which could result in compromised patient care and increased costs.  
The format of cytogenetic test result reports has been more standardized among 
different cytogenetics labs in comparison with formats of result reports used by other 
types of genetic tests. This is mainly because cytogenetics labs have been using the Inter-
national System for Human Cytogenetic Nomenclature (ISCN) as the gold standard of 
describing chromosome aberrations for almost 40 years. ISCN is critical in reporting cy-
togenetic test results; it was created by the International Standing Committee on Human 
Cytogenetic Nomenclature to represent the outcome of cytogenetic tests [6]. The College 
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of American Pathologists (CAP) checklist and the American College of Medical Genetics 
(ACMG) guidelines for cytogenetics indicate that current ISCN must be used in clinical 
reports [7,8]. 
ISCN provides a list of symbols and abbreviated terms in conjunction with a set 
of rules, such as p for short arm of the chromosome, q for long arm of the chromosome, 
cen for centromere, del for deletion, ish for in situ hybridization, and plus sign (+) for 
gain, etc. A cytogenetics test result defined in the ISCN notation provides precise, unam-
biguous descriptions of the cytogenetic findings. Example ISCN expressions are: 
“46,XX”, which indicates a normal female; “47,XY,+21”, which indicates a male with 
trisomy 21 (an extra copy of chromosome 21, commonly known as Down syndrome). 
The ISCN notation for arr copy number change and FISH results can be quite lengthy and 
include precise breakpoint designations at the detailed level of individual base-pairs. For 
example, “arr 20q13.2q13.33(51,001,876-62,375,085)x1,22q13.33(48,533,211-
49,525,263)x3” is an ISCN notation for a microarray analysis that shows a single copy 
loss on 20q and a single copy gain on 22q [6].  
The International Standing Committee on Human Cytogenetic Nomenclature has 
traditionally updated ISCN every 10 years. However, as the field of cytogenetics contin-
ues to include several molecular-based technologies, the latest revision of ISCN was pub-
lished in 2009—four years after the previous version—to provide more up to date and 
accurate descriptions of the new technologies, e.g., a new chapter was added with no-
menclature examples describing copy number detection due to rapid advancement in mi-
croarray technology [9].  
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Consolidated Health Informatics (CHI) initiative adopted Logical Observation 
Identifiers Names and Codes (LOINC) system as the standard vocabulary for observation 
identifiers for use in electronic exchange of laboratory test results in 2004 [10]. HL7 V2 
is considered to be the most widely implemented standard for healthcare information in 
the world. LOINC was initially designed to provide universal identifiers for observations 
sent in HL7 messages. Specifically, LOINC provides a code system for the observation 
identifier field (OBX-3) of the HL7 observation reporting message. Other fields in the 
HL7 messages provide additional semantic structures that are needed to reflect a model 
of laboratory testing orders and results observations. However, LOINC is now being used 
in other messaging standards, such as Digital Imaging and Communication in Medicine 
(DICOM) ultrasound messages and Clinical Data Interchange Standards Consortium 
(CDISC) pharmaceutical industry messages [11].   
LOINC 
The Regenstrief Institute is responsible for the development and maintenance of 
the LOINC database as well as the Regenstrief LOINC Mapping Assistant (RELMA) 
tool. RELMA is a program that provides LOINC users with functionalities such as 
browsing, searching, and mapping. Both LOINC and RELMA are freely available to the 
public [12]. A new LOINC web search tool is now also available for users to search 
LOINC codes online [13]. Since the Regenstrief Institute first released the LOINC codes 
to the internet in 1996, LOINC content has continued to grow and LOINC has become 
the most widely adopted standard for laboratory test result names in the United States and 
internationally. The latest LOINC database version 2.38, which was released in Decem-
10 
   
ber 2011, contains 68,350 terms. LOINC has been translated into several languages, and 
there are LOINC users in at least 145 countries.   
Each LOINC term consists of a six-part structure: component (analyte), kind of 
property, time aspect (timing), system (sample), type of scale, and type of method. Ex-
amples of component (analyte) include potassium and hemoglobin. Kind of Property con-
tains information about what kind of property was measured about the component, such 
as a mass concentration. Timing describes whether the measurement is an observation at 
a moment of time, or an observation integrated over an extended duration of time, such as 
24-hour urine. The type of sample is urine, blood, and skin, etc. The type of scale speci-
fies whether the measurement is quantitative, ordinal, nominal, or narrative. Method de-
scribes the process used to produce the result or other observation, and is optional in the 
six-part structure. Each LOINC part can be made of subparts. A fully specified LOINC 
name uses a colon character, “:”, to connect its six parts and a carat, “^”, to connect the 
subparts, for example, ABO group:Type:Pt:Bld^donor:Nom (ABO group in blood from 
donor). For convenience, a LOINC term may also have a unique short name in addition 
to its fully specified long name.  
LOINC panels are used to represent collections that have enumerated discrete 
contents by creating LOINC panel terms that are linked to an enumerated set of child el-
ements. The child elements are LOINC terms or panel terms themselves, the latter allows 
representation of a fully nested hierarchical structure. A LOINC panel child element has 
an attribute of cardinality, which specifies the allowable number of repetitions for an 
item.  
11 
   
LOINC answer lists are used to define allowable answers to a LOINC term. An-
swer lists could be an enumerated list of answers that reside internally in LOINC with an 
Object Identifier (OID) assigned to identify the entire answer list and a unique identifier 
assigned for each answer option. Answer lists could also be pointing to an external an-
swer list uniquely identified by an OID and code system.  
HL7 is one of several American National Standards Institute (ANSI) accredited 
Standards Development Organizations (SDO) operating in the healthcare arena. HL7 fo-
cuses on the data exchange requirements of the entire health care organization. It pro-
vides standards for interoperability that improve care delivery, optimize workflow, re-
duce ambiguity, and enhance knowledge transfer among healthcare providers, govern-
ment agencies, the vendor community, fellow SDOs, and patients [14].   
Health Level Seven 
An HL7 message is a hierarchical structure associated with a trigger event. A 
trigger event is an event in the real world of health care that creates the need for data to 
flow among systems, such as registering a patient. An HL7 message is a collection of 
segments; it includes the rules of repetition and inclusion for those segments. Examples 
of segments include Message Header (MSH), Patient Identification (PID), Observa-
tion/Result (OBX), and Observation Request (OBR). An HL7 segment is a group of 
fields each of which conforms to a particular data type. Fields can consist of components 
according to their data type definitions, and components may consist of subcomponents 
to represent complex structure. HL7 V2 messages use delimiters such as “|”, “^”, and 
“&” to separate fields, components, and subcomponents respectively. A carriage return, 
“<cr”>, is used to terminate a segment record. HL7 data type definitions are critical to 
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constructing HL7 V2 messages properly and to understanding and parsing the data con-
tents of an HL7 field.  
HL7 V2 was designed using an 80/20 approach to solve clinical interfacing prob-
lems in a flexible manner [15]. This practical solution led to the widespread acceptance 
of the standard, but also has led to its own challenges. The lack of precision (vagueness 
and flexibility allowed in the standard) is among some of the main challenges or weak-
nesses of the current HL7 V2 standards. Even though HL7 messages for order entry and 
results reporting were not designed with supporting genetic tests in mind, because of the 
flexibility allowed in HL7 V2 standards, we know we will be able to use HL7 V2 to 
transmit genetic test results reporting messages with customization. However, to allow all 
implementers, including vendors, laboratories, and healthcare facilities, to define inter-
faces for genetic test result reporting consistently, we need a mechanism to unambiguous-
ly represent the semantic relationships of observations contained in a clinical report and 
to couple it with the structure of HL7 V2 messages.  
HL7 implementation guides are balloted through HL7; they are implementation 
oriented and provide more detailed instructions for a specific use case. HL7 approved a 
new implementation guide for electronic exchange of results of genetic variation tests 
called the “HL7 Version 2 Implementation Guide: Clinical Genomics; Fully LOINC-
qualified Genetic Variation Model, Release 1” in 2009 [16]. This guideline was spon-
sored by the Clinical Genomics Work Group. The genetic variation model contains a set 
of four nested LOINC panels. Genetic Analysis Master Panel is the parent panel, which 
has exactly one Genetic Analysis Summary Panel and zero-to-one Genetic Analysis Dis-
crete Result Panels. The Genetic Analysis Discrete Result Panel has zero-to-many DNA 
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Analysis Discrete Sequence Variation Panels. Intermountain Healthcare and Partners 
Healthcare Center for Personalized Genetic Medicine have developed a pilot implementa-
tion of the guideline. The two organizations announced the first transmission of a coded 
and structured genetic test result sent electronically through the interface established be-
tween the two institutions, with the result being stored as part of the patient’s EHR [17]. 
However, this implementation guide covers only genetic test results for the identification 
of DNA sequence variations contained within a gene; it does not support the reporting of 
cytogenetic test results.  
HL7 has started the development of version 3 (V3) standards in the late 1990s to 
address problems inherent in V2 standards. HL7 V3 messages are derived from the un-
derlying HL7 Reference Information Model (RIM); this model based standard provides 
consistency across the entire standard, which is lacking in HL7 V2. HL7 V3 also has 
fewer message options, which is more rigorous than V2. However, HL7 V3 messages 
have not been widely adopted within the U.S. as a means to exchange clinical data. As of 
today, HL7 V3 has mainly been adopted by regions or environments where V2 was rarely 
or never used. In the U.S., because HL7 V2 has been so heavily implemented and sup-
ported by almost all EHR systems, it will not fade away any time soon. HL7 V2 and V3 
will likely coexist, especially where clinical documents are used, e.g., an HL7 V3 Clini-
cal Document Architecture (CDA) document could be sent in an HL7 V2 message. HL7 
V3 CDA, a document markup standard that specifies the structure and semantics of clini-
cal documents for the purpose of exchange, has gained wide acceptance worldwide, and 
within U.S. as well, largely driven by recent government legislation that specifies Mean-
ingful Use [18]. However, CDA was designed specifically for clinical documents; HL7 
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V2 and LOINC are the most widely implemented standards for laboratory orders and re-
sult reporting.  
Clinical decision support (CDS) systems have shown great promise for reducing 
medical errors and improving patient care. The Institute of Medicine identified computer-
ized clinical decision support as one of eight core functionalities that a successful EHR 
should incorporate to promote greater safety, quality, and efficiency in health care [19]. 
When effectively used, CDS can significantly improve clinical practice as shown in over 
90% of randomized controlled trials [20]. CDS is one of the core rationales for why the 
healthcare industry is now driving toward widespread use of EHRs.  
Clinical Decision Support 
CDS provides clinicians, staff, patients, or other individuals, with knowledge and 
person-specific information, intelligently filtered or presented at appropriate times, to en-
hance health and healthcare. Knowledge-based CDS systems typically contain three 
parts: the knowledge base, the inference engine, and a mechanism to communicate with 
the user [22]. Computer alerts at the time of order entry in a computerized provider order 
entry system, such as dose range checking for medications, drug-drug interactions, and 
drug-allergy checking, can help catch a critical source of human error [23,24]. CDS could 
potentially guide physicians toward ordering the most appropriate and cost effective tests 
at the point of ordering. Randomized trials have shown that computerized reminders and 
prompts increase the use of preventive care in both the outpatient and inpatient setting 
[25]. CDS also yields increased adherence to guideline-based care [26].   
As personalized medicine enters the healthcare delivery system, there will be in-
creased use of molecular tests and greater reliance on healthcare information systems for 
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decision support. Enhancing the use of CDS tools will provide just-in-time education and 
support the optimal use of genetics and genomics in health care, which will help to over-
come the shortage of healthcare professionals and public health providers trained in ge-
netics [27]. For example, tools like “infobuttons” could be implemented to establish links 
between coded problems in the problem list and relevant on-line genetic resources [28]. 
CDS can also trigger execution of a best practice guideline for a particular syndrome, 
such as the guidelines for children with Down syndrome [29].  
The combination of genetic/genomic information and EHRs provide a potentially 
rich data source for discovering correlations between diseases and for genome-wide asso-
ciation analysis. In addition to secondary use of EHR data for clinical research, the same 
approach can now be used to guide real-time clinical decisions, when existing literature is 
insufficient to guide the clinical care of a patient [30]. 
1  GeneTests. GeneTests. http://www.ncbi.nlm.nih.gov/sites/GeneTests/ (accessed 24 
Feb2012). 
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Genetic testing is becoming increasingly important to medical practice. Integrat-
ing genetics and genomics data into electronic medical records is crucial in translating 
genetic discoveries into improved patient care. Information technology, especially Clini-
cal Decision Support Systems, holds great potential to help clinical professionals take full 
advantage of genomics advances in their daily medical practice. However, issues relating 
to standard terminology and information models for exchanging genetic testing results 
remain relatively unexplored. This study evaluates whether the current LOINC standard 
is adequate to represent constitutional cytogenetic test result reports using sample result 
reports from ARUP Laboratories. The results demonstrate that current standard terminol-
ogy is insufficient to support the needs of coding cytogenetic test results. The terminolo-
gy infrastructure must be developed before clinical information systems will be able to 
handle the high volumes of genetic data expected in the near future.   
Abstract 
The successful completion of the Human Genome Project on April 14, 2003, 
marked the beginning of the “genome era,” and subsequent gene discoveries are leading 
to major advances in both diagnosis and treatment. The number of clinically available 
genetic tests is rapidly growing. When GeneTests, supported by the National Institutes of 
Health, started tracking laboratories providing genetic tests in 1993, there were 110 dis-
ease tests available. Today there are about 1700 disease tests available [1]. Genetics is 
becoming increasingly important to health care providers and genetic testing is being in-
tegrated into medical practice in many areas of medicine. Even though genomic advances 
promise to improve patient care, the explosion of information and knowledge in the areas 
Introduction 
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of genetics, genomics, and health care can be demanding. This information and 
knowledge explosion, coupled with the lack of integration of genetic testing information 
with traditional patient data, presents great challenges if we are to take full advantage of 
genomic advances in medical practice.  
Many physicians have reported a lack of basic knowledge and confidence about 
medical genetics, which limits their ability to appropriately counsel their patients and ac-
curately interpret genetic tests [2].  Missed opportunities for health professionals to edu-
cate patients and families regarding genetics have been identified [3]. In addition to the 
competency of medical staff, the variation and format of test requisitions and result re-
ports have contributed to poor communication between testing laboratories and clinicians 
[4]. The quality of patient care may be compromised as a consequence.   
The importance of standardizing genetic test result reports is well recognized. Ef-
forts have already begun to address this issue within the laboratory testing industry. For 
example, some model reports for molecular genetic testing have been developed and the 
College of American Pathologists (CAP) provides a checklist for result reporting [2,5]. 
However, little has been done to address how to use information technology to improve 
the use of genetic test results in medical practice. In particular, the use of standard con-
trolled terminology and information models for exchanging and storing genetic test result 
reports in Electronic Medical Records (EMRs) remains relatively unexplored.   
It is widely agreed that information technology, especially Clinical Decision Sup-
port Systems (CDSS), has the potential to reduce medical errors, and to improve quality, 
safety, and efficiency of health care. Bringing genetic tests results into the patient’s EMR 
is one of the essential first steps in translating genetics and genomic knowledge into daily 
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medical practice. However, it will be very difficult to apply decision support if the genet-
ic test results are simply transmitted and stored as narrative text or as images in the EMR. 
Establishing standard logical representations for genetic data using controlled terminolo-
gies and information models is a prerequisite to establishing genetic CDSS as part of an 
EMR system.  
The Logical Observation Identifiers Names and Codes (LOINC) system was 
adopted by the Consolidated Health Informatics (CHI) initiative as the standard vocabu-
lary for observation identifiers for use in electronic exchange of laboratory test results. 
Health Level Seven (HL7) version 2 is considered to be the most widely implemented 
standard for healthcare information in the world. LOINC was designed to provide univer-
sal identifiers for observations sent in messages in data exchange standards like HL7 and 
Digital Imaging and Communication in Medicine (DICOM). For example, LOINC pro-
vides a code system for the observation identifier field (OBX-3) of the HL7 observation 
reporting message. Other fields in the HL7 messages provide additional semantic struc-
tures that are needed to reflect a model of laboratory testing orders and results observa-
tions. Since the first release of LOINC over 10 years ago, LOINC content has continued 
to grow and LOINC has become the most widely adopted standard for laboratory test re-
sult names in the United States and internationally.  
Clinical cytogenetics is the study of the genetic constitution of individuals by ex-
amining the structure and organization of chromosomes. Chromosome tests were intro-
duced into clinical practice in the late 1950s. Constitutional cytogenetic tests can detect 
pre-existing numerical and structural abnormalities prenatally or after birth. Chromoso-
mal abnormalities have been found to be the etiology for a number of multiple congenital 
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anomaly syndromes as well as isolated mental retardation and developmental delay. Cer-
tain chromosomal abnormalities are consistently associated with medical conditions that 
require screening and management for the affected patient. Given their rarity and the lack 
of readily available clinical information, these conditions present excellent opportunities 
for CDSS.  
The International System for Human Cytogenetic Nomenclature (ISCN) was cre-
ated by the International Standing committee on Human Cytogenetic Nomenclature to 
represent the outcome of cytogenetic tests. The latest version of ISCN was published in 
2009. One of the aims of ISCN is to prevent confusion in reporting research cytogenetics 
results. ISCN is accepted as a standard within the industry. It specifies the nomenclature 
to describe karyotypes, chromosome abnormalities, in situ hybridization, etc. The CAP 
checklist for cytogenetics includes an item to assure that current ISCN is used correctly in 
a final report.   
The goal of the current study is to formulate a model for the electronic exchange 
of coded cytogenetic test results and to determine how LOINC codes fit into the model, 
and to evaluate whether current LOINC codes are adequate to support this use case.     
The latest LOINC database release Version 2.26 was selected as the basis for this 
evaluation. This version contains 53,344 terms.  We first searched the LOINC database 
using RELMA (a mapping and browsing tool provided with the LOINC database) to re-
trieve genetic related LOINC concepts. We used the key word “MOLPATH” to select the 
relevant content. “MOLPATH” represents Molecular Pathology, the class under which 
genetic related LOINC terms are grouped. To confirm the search results, we also 
Materials and Methods 
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searched the LOINC table directly. The LOINC table was filtered using “MOLPATH” 
and any of its subclasses as the filter values for the “class” column. The subclasses of 
MOLPATH are “MOLPATH.MUT”, “MOLPATH.DEL”, “MOLPATH.TRISOMY”, 
“MOLPATH.TRNLOC”, “MOLPATH.TRINUC”, “MOLPATH.REARRANGE”, 
“MOLPATH.GENERAL”, and “MOLPATH.MISC”. The “class” filter was also used to 
select three additional classes: “PANEL.MOLPATH”, “HL7.GENETICS”, and “PAN-
EL.HL7.GENETICS”. The same number of LOINC terms was returned from the filter 
results as from the original RELMA query. We then manually went through each of the 
genetic LOINC concepts to select the ones that are specifically for cytogenetic testing.   
To evaluate whether the current LOINC terminology is sufficient to represent 
constitutional cytogenetic test names and their results, we tried to represent a list of key 
data elements found in cytogenetic result reports by using the existing LOINC concepts. 
We obtained sample constitutional cytogenetic test result reports from the Cytogenetics 
Section of ARUP Laboratories. ARUP is a national clinical and anatomic pathology ref-
erence laboratory owned by the University of Utah [6]. The sample result reports were 
chosen so they would cover tests that were done using different cytogenetic techniques 
including: conventional G-banding, fluorescence in situ hybridization (FISH), and micro-
array based comparative genomic hybridization (array-CGH). The sample reports also 
represented a variety of results, including normal, abnormal, and findings of unknown 
clinical significance. We examined these sample result reports and extracted a list of key 
data elements that should be coded.  We also obtained the names of constitutional cyto-
genetic tests offered by ARUP from its online test menu. 
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Table 2.1
Results 
 shows the list of key data elements extracted from the constitutional cy-
togenetic test result reports that should be coded. We did not include some standard data 
elements in lab result reports, such as patient date of birth, sex, the specimen type, speci-
men collection date, reason for referral, etc. These elements should be sent in other fields 
in the HL7 message, and should not be sent as test results in the observation segment us-
ing LOINC codes. 
The constitutional cytogenetic tests offered by ARUP are listed in Table 2.2. 
A total of 1001 genetic related LOINC terms were found in the database. Among 
these terms, the majorities were related to mutation analysis; only 36 terms were cytoge-
netic test related concepts.  The first part of the LOINC name is the component or analyte 
measured. Table 2.3 lists the 20 distinct LOINC components from the 36 LOINC names.  
Some of the components were used in several LOINC names in combination with differ-
ent systems, properties, scales, or methods.   
We found that the current LOINC terms for cytogenetic tests are not consistent 
with how the ARUP cytogenetic tests are named or with how the results are represented 
in actual reports. The existing LOINC terms are not consistent with the vocabulary need-
ed to represent ARUP cytogenetic test names and results. 
To report a chromosome analysis result for a male with Trisomy 21 (Down syn-
drome), the ARUP result report includes “Chromosome Analysis, Peripheral Blood” as 
the test name. This test name could be mapped to the LOINC code “Karyo-
type:Prid:Pt:Bld/Tiss:Nar”. For the test result, ARUP reports it as “47,XY,+21”, which is 
the ISCN representation for male, Trisomy 21. The existing LOINC codes do not support 
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this reporting style. Instead, they attempted to pre-coordinate the findings into the result 
names, e.g. Chromosome 21 trisomy:Arb:Pt:Bld/Tiss:Ord:Cytogenetics. This style of 
pre-coordination implies that the value of the result for this test as named by LOINC 
would be “Present” or “Absent.” 
For FISH studies, LOINC codes exist for Chromosome analysis, FISH-Interphase, 
but no codes exist for Chromosome Analysis, FISH-Metaphase. No codes are currently 
available to properly represent the results for any of the common microdeletion syn-
dromes using either the LOINC variable approach or the panel approach. For example, 
consider DiGeorge/Velco-Cardio-Facial syndrome with the ISCN representation “ish 
del(22)(q11.2q11.22)(HIRA-)”. To represent this finding using a panel approach, we 
would need a LOINC code that pre-coordinates the 22q11.2 deletion into the LOINC 
name. To represent it using the variable approach, a LOINC term like “chromosome 
analysis FISH result” would need to be created. 
No LOINC codes currently exist to represent the array-CGH tests and their re-
sults. 
The number of terms in the latest LOINC release for genetic test observations, es-
pecially cytogenetic tests, is minimal. We suspect that the existing LOINC terms are not 
being used in production systems because the existing LOINC terms and what is being 
reported from ARUP imply very different models of representation. These terms do not 
match well with how the tests are named and how the test results are reported.   
Discussion 
Recognizing the importance of genetic test result reporting, the LOINC commit-
tee recently began developing terms for representing genetic variations.  However, there 
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is no specific section in the LOINC Reference Manual that discusses names and codes for 
cytogenetic tests. We plan to propose developing the needed cytogenetic codes in part-
nership with the LOINC committee. 
Pre-coordination vs. Post-coordination 
The majority of existing LOINC terms for cytogenetic tests are taking the pre-
coordination approach. The current style of LOINC terms seems to have been created to 
ask questions like whether a given abnormality is found, e.g. 18q chromosome dele-
tion:Prid:Pt:Bld/Tiss:Nom:Molgen, with the expected answers being “Present” or “Ab-
sent”.  Continuing this style of LOINC name creation will be problematic, not only for 
the representation of cytogenetic test results but also for the representation of genetic test 
results in general. Due to the ever growing and changing nature of this field, this pre-
coordinated style of name creation will likely lead to a large number (and potentially lim-
itless) of test names being created. For example, the U-Array Chip that ARUP currently 
uses for its array-CGH test contains close to 150 targeted regions and this number will 
continue to grow as higher density chips come into practice. In order to avoid combinato-
rial explosion, a post-coordinated style would be more appropriate for creating LOINC 
concepts for genetic testing as it will be more sustainable and flexible. 
ISCN and Coded Expression Data Type 
Compared to molecular genetic tests results, the advantage that cytogenetic test 
result reporting has is that ISCN has been the gold standard for describing chromosome 
aberrations for almost 40 years.  ISCN provides a list of symbols and abbreviated terms 
in adjunction with a set of rules, which can be used in the description of chromosomes 
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and chromosome abnormalities, such as p for short arm of chromosome, q for long arm 
of chromosome, cen for centromere, del for deletion, ish for in situ hybridization, and 
plus sign (+) for gain, etc. 
Data that are expressed in ISCN nomenclature need to be distinguished from ei-
ther string values or concepts from a code system.  Typical behaviors that are expected 
for coded concepts do not apply to ISCN expressions.  This situation is the use case that 
would justify a new “coded expression” data type for use in HL7 messages.  It might also 
suggest the need for a new type of scale in the LOINC terminology. When receiving sys-
tems encounter coded expressions, tools will need to parse the data rather than to do ter-
minology look ups. This would also imply the need for a new query engine that could 
query against the ISCN expressions. For example, as new knowledge becomes available 
it would be desirable to run a query to identify all patients who have chromosome ab-
normalities that were believed to be clinically insignificant or that have unknown clinical 
significance at the time of testing where a revised report should be issued. The results re-
view applications will also need to be able to present this new type of data rather than 
treating them the same as simple name-value pairs. 
Array-CGH 
Array-CGH merges molecular diagnostics with traditional chromosome analysis 
and is transforming the field of cytogenetics. Array-CGH holds the promise of being the 
initial diagnostic tool in the identification of visible and submicroscopic chromosome ab-
normalities in mental retardation and other developmental disabilities [7–9]. Therefore, 
clinical information systems should anticipate receiving more array-CGH results in the 
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very near future. The LOINC standard should examine this rapidly growing area and de-
velop codes for microarray based laboratory tests. 
Terminology and Information Models 
The LOINC terminology without the context of an information model is not suffi-
cient to unambiguously exchange cytogenetic test results. The LOINC codes need to be 
developed in the context of an information model, which is similar to putting vocabulary 
terms into meaningful sentence structures. In addition to the LOINC standard, other bio-
informatics standard terminologies such as ISCN are necessary to represent the detailed 
results of cytogenetic tests. 
Limitations 
Our evaluation may be limited due to the fact that there is lack of industry wide 
cytogenetic result report standards available. As a consequence our analysis is based on 
sample result reports from ARUP only. However, because ARUP result reports contain 
all the data elements listed on the CAP checklist (which represents the industry standard), 
this limitation is likely minimal.  
Another limitation is that the list of key data elements that we included for analy-
sis is not complete. We did not extract data elements from the free text sections of the 
report such as the “diagnostic impression” and “recommendation” sections of the reports. 
This means that our evaluation of current reporting limitations is likely conservative. 
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Conclusion and Future Work 
Current LOINC terminology is insufficient to support the needs of coding cytoge-
netic test results. With genetic testing becoming an increasingly important part of the dai-
ly medical practice, we need to develop this essential infrastructure before clinical infor-
mation systems will be able to handle high volumes of genetics data.   
This study was an initial step in integrating cytogenetic test result reports into 
EMRs. It demonstrated that a gap exists in LOINC in supporting such integration. Work 
needs to be done to extend LOINC to cover cytogenetic tests and to continue to expand 
the codes needed for the broader field of genetic variation testing.  Since it is the CHI 
designated standard for laboratory tests, we suggest enhancing and extending LOINC to 
represent cytogenetics test result reports rather than creating them in some other existing 
terminology.   
Further analysis needs to be done to develop new LOINC codes and information 
models to represent the constitutional cytogenetic test result reports. The analysis needs 
to be expanded to include result reports from other laboratories besides ARUP. Structur-
ing the diagnostic impression and recommendation section of the result report needs to be 
addressed as well. Our hope is that this will lead to consistency in reporting results, in 
addition to simplifying access to and understanding of interpretation of those results.  
We would like to thank Drs. Peter Haug and Scott Narus for reviewing the article, 




   
Table 2.1. Key data element in constitutional cytogenetic test result reports 
Data Element 
Test Performed 
Chromosome Result (expressed in ISCN) 
FISH Result (expressed in ISCN) 
Array-CGH Result (expressed in ISCN) 
Number of cells counted  
Number of colonies counted 
Number of cells analyzed 
Number of cells karyotyped 
ISCN Band Level 
Banding Method 
Copy number change 
Chromosome bands involved  
Base pair coordinates 
 
 
Table 2.2. Constitutional cytogenetic tests offered by ARUP 
Test # Test Name 
0097779 Prenatal FISH (Chromosomes X, Y, 13, 18 &21) 
0097615 Chromosome Analysis, FISH-Metaphase  
0092615 Chromosome Analysis, FISH-Interphase 
0040201 Genomic Microarray, U-Array Chip 
0097640 Chromosome Analysis, Peripheral Blood 
0097601 Chromosome Analysis, Amniotic Fluid 
0097610 Chromosome Analysis, Chorionic Villus Sampling (CVS) 
0097620 Chromosome Analysis, Fetal Blood (PUBS) 
0097645 Chromosome Analysis, Products of Conception (POC) 
0097655 Chromosome Analysis, Skin Biopsy 










   
Table 2.3. Distinct LOINC components from the 38 existing cytogenetic test re-
lated concepts 
 
Test # Test Name 
0097779 Prenatal FISH (Chromosomes X, Y, 13, 18 &21) 
0097615 Chromosome Analysis, FISH-Metaphase  
0092615 Chromosome Analysis, FISH-Interphase 
0040201 Genomic Microarray, U-Array Chip 
0097640 Chromosome Analysis, Peripheral Blood 
0097601 Chromosome Analysis, Amniotic Fluid 
0097610 Chromosome Analysis, Chorionic Villus Sampling (CVS) 
0097620 Chromosome Analysis, Fetal Blood (PUBS) 
0097645 Chromosome Analysis, Products of Conception (POC) 
0097655 Chromosome Analysis, Skin Biopsy 
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CHAPTER 4 
CYTOGENETICS LOINC CODES DEVELOPMENT 
To develop Logical Observation Identifiers Names and Codes (LOINC) codes to 
represent constitutional cytogenetic test results for electronically exchanging coded and 
structured result reports. The LOINC codes developed must be flexible and sustainable 
for easy maintenance. The goal is to create a standard set of codes that are flexible 
enough to be used for all unique conventional and molecular cytogenetic results.   
Abstract 
Patient de-identified sample result reports were obtained from ARUP Laborato-
ries for a variety of normal and abnormal constitutional studies using G-banding, FISH 
and array-CGH.  Information models were created to capture the semantic relationships 
of the key data elements that existed in the reports. Sample reports were subsequently 
obtained from Emory and Mayo Clinic Cytogenetics Laboratories to verify the infor-
mation models. The information models were then used to guide the systematic creation 
of the LOINC codes.   
A post-coordinated approach was used in developing the LOINC codes for 
cytogenetics test results. LOINC panel codes were created to represent the hierarchical 
structures implied by the reports. A master panel was created to contain three LOINC 
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subpanels; each of the three subpanels held the structure for chromosome analysis results 
that uses a different technique.   
The LOINC codes we created met our objective and will allow the use of well es-
tablished health informatics standards to exchange coded and structured cytogenetic test 
results between testing laboratories and ordering institutions. Use of standard structures 
and terminologies for cytogenetic results is critical for effective communication between 
testing laboratories and clinicians. This minimizes misinterpretation, leads to consistency, 
and provides the EHR systems flexibility of customizing formatting to present more cli-
nician-friendly reports.  
Discoveries in genetics and genomics research are increasing at a rapid rate. The 
number of clinically available genetic tests has also increased dramatically during the 
past decade [1,2]. From primary care to specialty care settings, genetic testing is changing 
many aspects of clinical practice and patient services. Integration of genetic and genomic 
data with traditional clinical data to support the diagnostic and treatment decisions at the 
point of care for the individual patient is touted as ushering in a new era of personalized 
medicine [3–5].  
Introduction 
Realization of the promise of personalized medicine depends on effective com-
munication between laboratories and clinical settings. The laboratory result report plays a 
vital role in this communication channel. However, the format of genetic test requisitions 
and result reports vary from laboratory to laboratory; test results lack clarity about the 
clinical significance of the findings and are not clinician friendly [6]. All these factors 
have affected efficient communication between testing laboratories and clinicians. The 
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problem has been further compounded by clinical providers’ lack of basic knowledge 
about genetics, and their lack of confidence in interpreting genetic results [7,8]. This 
could lead to potential misinterpretation of test results and compromised patient care; ge-
netic test result reports that use standardized terminology and improved formatting are 
critical to address these problems. 
Realization of the benefits provided by genetic and genomic advances in clinical 
care depends on effective access to the right information at the right time. Electronic 
Health Records (EHRs) promise to improve patient care, especially by providing ad-
vanced Clinical Decision Support (CDS) at the point of care.  Incorporating genetic test 
results into the patient’s EHR is a major step forward to take full advantage of genet-
ic/genomic advances in clinical practice. However, EHRs today require significant modi-
fications in order to consume genetic/genomic information and to effectively utilize such 
information in making clinical decisions [9,10]. 
Standard terminologies that are tightly coupled with standard information models 
are the foundations of developing CDS-enabled EHRs. However, current standard termi-
nologies for genetic test results are not sufficient. As the movement toward predictive, 
personalized, preventive medicine accelerates, we must develop terminology infrastruc-
ture before clinical information systems will be able to handle the high volumes of genet-
ic and genomic data expected in the near future.   
We previously evaluated the Logical Observation Identifiers Names and Codes 
(LOINC) system for representing cytogenetic test names and their results [11]. LOINC is 
the most widely adopted standard for laboratory test result names in the United States and 
internationally [12]. We found that current LOINC content is not sufficient to encode cy-
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togenetic test names and test results. In this article, we describe how new LOINC codes 
for constitutional cytogenetic test results were developed. As the demand for standard 
terminologies representing genetics and genomics data continues to increase, the ap-
proach we took and the experiences we gained through this development process may be 
especially useful for others to use when developing standard terminologies to support the 
integration of genetic and genomic data into EHRs. Others may also find our approach 
useful for developing standard terminologies in general. 
Cytogenetic Test 
Background 
Cytogenetic tests evaluate chromosomes from the nucleus of the cell for changes 
in number or structure.  Cytogenetic testing is used in various clinical situations. These 
historically included assessment of a developmentally delayed child, evaluation of a can-
cerous tumor, or prenatal studies to detect chromosomal anomalies in a fetus [13]. A con-
stitutional cytogenetic abnormality is one which occurs in the germline. A cancerous cy-
togenetic abnormality is an acquired (somatic) genetic change associated with a neo-
plastic process.  
The emerging field of cytogenomics includes conventional cytogenetics, which 
uses chromosomal banding techniques such as G-banding, in addition to molecular tech-
nologies, such as fluorescence in situ hybridization (FISH), and cytogenomic microarray 
(arr). FISH is often used in prenatal diagnosis when results are needed rapidly to detect 
chromosomal aneusomies such as Down syndrome (trisomy 21), and also to detect chro-
mosomal deletions, duplications, or rearrangements that are not visible using microsco-
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py.[14]. Cytogenomic microarray (arr) circumvents a limitation of FISH as it does not 
require foreknowledge of the chromosomal loci being evaluated.  
The introduction of arr to clinical cytogenetics has facilitated the genome-wide  
detection of DNA copy number imbalances at resolutions significantly higher than previ-
ously attainable [14]. Arr analysis allows for the simultaneous analysis of hundreds or 
thousands of discrete loci, not possible within a single FISH experiment and at a much 
higher resolution than conventional cytogenetic analysis. Although current arr technolo-
gies cannot identify balanced rearrangements, most chromosome analyses that are per-
formed on individuals with phenotypic abnormalities, developmental delays, or intellec-
tual disability are performed to detect unbalanced chromosomal rearrangements, (gains 
and losses of chromosomal segments) and have been proposed to be a first tier test [15]. 
Traditional cytogenetics methods can detect gross chromosomal lesions. G-
banded karyotyping is generally limited to the detection of genomic imbalances in the 5-
10 Mb range. Most FISH assays used in a clinical cytogenetic setting detect submicro-
scopic changes no smaller than 50 kb, and only in limited targeted areas. In contrast, 
available oligonucleotide platforms can now detect genomic imbalances as small as 500 
bp [16], and the International Standard Cytogenomic Array Consortium (ISCA) currently 
recommends a resolution of >=400 kb throughout the genome as a balance of analytical 
and clinical sensitivity to detect copy number variants [15]. 
The International System for Human Cytogenetic Nomenclature (ISCN) is critical 
in reporting cytogenetic test results. ISCN was created by the International Standing 
Committee on Human Cytogenetic Nomenclature to represent the outcome of cytogenetic 
tests [17]. The latest version of ISCN was published in 2009. ISCN has been the gold 
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standard of describing chromosome aberrations for almost 40 years. The College of 
American Pathologists (CAP) checklist and the American College of Medical Genetics 
(ACMG) guidelines for cytogenetics indicate that current ISCN must be used in clinical 
reports [18,19]. 
Cytogenetic Test Results from ARUP to Intermountain Healthcare  
Intermountain Healthcare is a nonprofit integrated health care delivery system 
consisting of 22 hospitals, and more than 130 outpatient clinics. Cytogenetic tests ordered 
by Intermountain physicians are performed by the ARUP Laboratories. ARUP is a na-
tional clinical and anatomic pathology reference laboratory owned by the University of 
Utah [20]. 
Cytogenetic test results are transmitted electronically from ARUP Laboratories to 
Intermountain Healthcare through Health Level Seven (HL7) version 2.x messages. HL7 
version 2.x standards are the most widely implemented standards for healthcare data ex-
change in the world. HL7 version 2.x defines a series of electronic messages to support 
administrative, logistical, financial as well as clinical processes [21]. Each HL7 version 
2.x message is composed of a number of segments. Each segment begins with a three-
character literal value that identifies it within a message. For example, NTE represents a 
Notes and Comments segment, which is used to transmit free text notes and comments; 
OBX represents an Observation/Result segment, which is used to transmit a single obser-
vation or observation fragment. A segment contains a group of logically combined data 
fields. HL7 v2.x mostly uses a textual, non-XML encoding syntax based on delimiters, 
such as “|” and “^”.   
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After the cytogenetic test results are received electronically by Intermountain 
Healthcare, they are stored in Intermountain’s Clinical Data Repository (CDR) [22]. 
However, the results are not sent in a coded and structured format. The report is con-
tained in an HL7 NTE segment as a text blob, and is stored as narrative text in the CDR. 
The test codes that are sent in the OBX-3 segment are local codes; they are not mapped to 
LOINC. One reason for this is that there are very few LOINC codes available for coding 
cytogenetic tests and results. A second reason is that the existing LOINC codes are not 
consistent with how the ARUP cytogenetic tests are named or with how the results are 
represented in actual reports [11]. For example, no LOINC code is available for repre-
senting the cytogenetic test results that are expressed in ISCN. 
HL7 Standard for Reporting Genetic Test Results 
HL7 approved a new implementation guide for electronic exchange of results of 
genetic variation tests called the “HL7 Version 2 Implementation Guide: Clinical Ge-
nomics; Fully LOINC-qualified Genetic Variation Model, Release 1” in 2009 [23]. This 
guideline was sponsored by the Clinical Genomics Work Group. The Genetic Variation 
Model contains a set of four nested LOINC panels; the parent panel is Genetic Analysis 
Master Panel, which has exactly one Genetic Analysis Summary Panel, and zero-to-one 
Genetic Analysis Discrete Result Panel. The Genetic Analysis Discrete Result Panel has 
zero-to-many DNA Analysis Discrete Sequence Variation Panel.  
Intermountain Healthcare and Partners Healthcare Center for Personalized Genet-
ic Medicine have developed a pilot implementation of the guideline. The two organiza-
tions recently announced the first transmission of a coded and structured genetic test re-
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sult sent electronically through the interface established between the two institutions, 
with the result being stored as part of the patient’s EHR [24]. 
However, this HL7 standard and the implementation effort are focused on report-
ing genetic test results performed using sequencing or genotyping technology for the 
identification of DNA sequence variations contained within a gene [23]. To our 
knowledge, no similar work has been done or is ongoing for exchange of cytogenetic test 
results. The development effort that we describe in this article aims to fill the gap in ex-
isting standards for cytogenetic test result reporting. 
After receiving IRB approval, we obtained patient de-identified sample result re-
ports for constitutional cytogenetics analyses from ARUP Laboratories. The sample re-
sult reports were chosen so they would cover tests that were performed using different 
types of cytogenetic techniques including G-banding, FISH, and arr. The sample reports 
also represented a variety of results, including normal, abnormal, and “findings of un-
known clinical significance.” We also obtained test names from the ARUP online test 
menu. We analyzed the sample result reports and extracted a list of key data elements that 
existed in the reports.  Before we made any new LOINC terms, we first created infor-
mation models that capture the semantic relationships of these data elements. The infor-
mation models were then used to guide the systematic creation of the LOINC codes. 
Formulation Process 
To ensure that the information models and the LOINC codes that would be devel-
oped could be generalized to other institutions besides ARUP, we contacted two other 
large cytogenetics laboratories in the country to request the same variety of sample pa-
tient de-identified test names and result reports from them. We received sample reports 
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from the Mayo Clinic Cytogenetics Laboratory (Mayo) as well as the Emory 
Cytogenetics Laboratory (Emory). The sample result reports for each laboratory were an-
alyzed, and their key data elements were also extracted.  We evaluated the new data ele-
ments and new relationships that were identified in the Mayo and Emory reports, which 
did not exist in the ARUP reports, and analyzed whether the information model required 
modification to accommodate the new data elements. 
After we had established the information models for cytogenetic test results based 
on reports from these three cytogenetics laboratories, we compared the cytogenetics 
model with the HL7 V2 Genetic Variation model. The goal was to reuse the common 
structure and the existing LOINC codes that are defined in the Genetic Variation model 
as much as possible. 
In the end, we created proposed LOINC codes for unique data elements that were 
contained in the cytogenetics models. Following the same strategy that was used to de-
velop the HL7 V2 Genetic Variation Model, LOINC panel codes were created to repre-
sent the hierarchical structures implied by the reports. To avoid proposing creation of du-
plicate codes in the LOINC database, the LOINC database was searched thoroughly be-
forehand, and any potential matching codes were analyzed to see whether they fit our 
needs and should be reused. The LOINC codes have been accepted by the LOINC Com-
mittee and are included in version 2.34 of the LOINC data base that was released in De-
cember 2010. 
We created three information models based on the sample clinical reports from 
ARUP, Mayo, and Emory cytogenetics laboratories. Figures 3.1 to 3.3 show the infor-
Model Description 
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mation models for conventional chromosome studies using G-banding, FISH studies, and 
arr studies respectively. The information models contain data elements such as chromo-
some analysis result and chromosome analysis overall interpretation. We did not include 
the specimen type as an attribute in the information models, since specimen is represent-
ed by one of the six LOINC axes and the LOINC code is carried in HL7’s observation 
identifier. We have also excluded standard data elements, such as patient date of birth, 
administrative sex, and specimen collection date, which are a routine part of laboratory 
reporting, and are carried by dedicated fields in segments that are a routine part of an 
HL7 observation message, rather than as separate OBX segments identified with special-
ized LOINC codes. Because ISCN descriptors can change over time, accurate interpreta-
tion of cytopathology reports requires knowledge of the ISCN version number used to 
generate the report. We have not had to include the ISCN version number in our infor-
mation model for cytogenetics reports because the version of a code system is part of the 
internal structure of the HL7 “coded with exception” (CWE) data type. Because of the 
changes in the ISCN coding system over time, the receiving EHR system will also have 
to keep the ISCN version number with cytogenetics test results it stores in the CDR. 
We created a set of nested LOINC panel codes that define the hierarchical struc-
ture of the results. The overall parent is, “Chromosome analysis master panel in Blood or 
Tissue” (LOINC # 62389-2). It contains three panels, which define, respectively, the re-
sults of a G-Band, FISH and arr study: “Chromosome analysis panel in Blood or Tissue 
by Banding” (LOINC#62355-3), “Chromosome analysis panel in Blood or Tissue by 
Fluorescence in situ hybridization” (FISH) (LOINC# 62367-8) and “Chromosome analy-
sis microarray copy number change panel in Blood or Tissue by arrCGH” (arr) (LOINC 
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#62343-9). The LOINC terms within the each panel carry data types, cardinalities and 
descriptions. For LOINC terms that have categorical values, we also created pre-defined 
answer lists. As shown in Figure 3.4. Chromosome analysis master panel, the chromo-
some analysis master panel contains at least one of the G-banding, FISH, or arr copy 
number change panel, and a required chromosome analysis summary panel. The master 
panel allows the laboratory to report results of individual G-banding, FISH, or arr copy 
number change test results alone, or as two or more of the three tests combined. 
The chromosome analysis summary panel must contain one chromosome analysis 
overall interpretation, which is the overall interpretation of the test. A LOINC answer 
list, whose values can be “normal,” “abnormal,” or “clinical significance unknown,” is 
provided with this code. The master panel contains one genomic source class, whose 
LOINC code has an answer list with coded values such as “germline,” “somatic,” and 
“prenatal.” The summary panel may have zero to many genetic disease assessed ele-
ments, and an optional genetic analysis summary report element. The summary report 
permits the lab to send a traditional narrative report embedded in the message. The chro-
mosome analysis summary panel beneath the master panel will always report the overall 
summary of the test results. If only one method (G-banding, FISH, or arr) is used during 
the chromosome analysis, the optional chromosome analysis summary panel that is con-
tained under each G-banding, FISH, or arr copy number change panel should not be used. 
For a given test, if multiple methods are applied, then the chromosome analysis summary 
panel at the higher level would allow an overall summary to be presented, and the chro-
mosome analysis summary panel at the lower levels of each multiple method will allow 
summary at individual levels to be reported. The summary panel must also contain a 
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chromosome analysis result in ISCN expression; i.e., a cytogenetics test result defined in 
the ISCN syntax - which provides precise, unambiguous descriptions of the cytogenetic 
findings. For example: “46,XX”, which indicates a normal female; and “47,XY,+21”, 
which indicates a male with trisomy 21 (an extra copy of chromosome 21, commonly 
known as Down syndrome). These are the two simplest examples; the ISCN notation for 
arr copy number change and FISH results can be quite lengthy and include precise break-
point designations at the detailed level of individual base-pairs. For example, “arr 
20q13.2q13.33(51,001,876-62,375,085)x1,22q13.33(48,533,211-49,525,263)x3” is an 
ISCN notation for a microarray analysis that shows a single copy loss on 20q and a single 
copy gain on 22q [17]. 
In addition to the summary panel, G-banding, FISH, and arr copy number change 
panels include discrete information that is specific to the technique. For example, it is 
important to report the human reference sequence assembly release number for an arr 
analysis. This indicates which version of the human assembly was used for the analysis.  
We formed HL7 version 2.5.1 standard messages based on the LOINC codes that 
we developed to represent the content of sample cytogenetic reports from three laborato-
ries: ARUP, Emory, and Mayo. Figure 3.5 shows the HL7 version 2.5.1 representation of 
the G-banding chromosome analysis report presented in Figure 3.6. Figure 3.7 shows the 
HL7 v2.5.1 message for the arr report of copy number changes presented in Figure 3.8. 
Validation Through Example 
In a message, nested Observation Request (OBR) segments are used to reflect the 
LOINC panel structures. OBRs are nested via links expressed in OBR-29-parent field, the 
same technique used in the HL7 implementation guide for genetic variation results [23]. 
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The LOINC codes contained in a panel correspond to the Observation (OBX) segments. 
Each new panel of observations begins with an OBR segment that carries the LOINC 
code for that panel and is followed by a series of OBX’s, each of which carries the 
LOINC code (OBX-3 field), and the value (OBX-5 field). For example, to represent the 
overall interpretation that the arr chromosome analysis test is abnormal: OBX-3 holds the 
LOINC code for “chromosome analysis overall interpretation”; the concept for “Abnor-
mal” is placed in OBX-5 as the value. Figure 3.9 illustrates how the cytogenetic LOINC 
codes fit into the nested OBR and OBX structure in HL7 version 2 messages.  
We picked 20 cytogenetics reports across a wide spectrum including FISH, G-
banding, and arr to verify that the proposed HL7 version 2 message had a place for ex-
pressing all of the most important information in these reports. We dissected these result 
reports based on the LOINC panels and codes. By dissecting these reports, we were able 
to represent all of the key data elements contained in the result reports in coded and struc-
tured format using the information models and the LOINC codes that we developed. 
The Secretary of the Department of Health and Human Services stated at the 
American Health Information Community (AHIC) meeting on September 12, 2006, 
“…genomics will play an increasingly larger role in medicine, and now is the time to fig-
ure out how best to incorporate genetic information into e-health records, before multiple 
nonstandard approaches take hold”  [25]. A survey published in 2009 has identified lack 
of standards for data elements, terminology, structure, interoperability, and clinical deci-
sion support rules as some of the major barriers and challenges to the integration of ge-
netic/genomic information with clinical data [9]. As information and knowledge of genet-
Discussion 
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ics/genomics continue to rapidly expand, providers will require point of care education 
and CDS system integrated into EHRs to remain current with the best practice guidelines 
and to take full advantage of genetic/genomic advances in medical practice. Our devel-
opment effort has extended LOINC coverage for genetic sequencing test results to 
cytogenetics. The information models we created enable the transmission of structured 
constitutional cytogenetic test results electronically from the testing facilities to the order-
ing institution, for incorporation into the EHRs. Such integration could minimize the op-
portunity for misinterpretation of the results. And this can be done with existing HL7 
messages and infrastructure. 
The standardization of genomic data representation is a vital component of a na-
tional CDS infrastructure to enable the widespread and consistent usage of genomic data 
and the practice of personalized medicine [10]. The information models and the set of 
associated LOINC codes that we created are an essential step toward the efficient use of 
molecular cytogenetics data in health care, decision support and research. By integrating 
structured test results and coded answers into a patient’s EHR, best practice guidelines 
can be triggered for specific syndromes. Through research that tracks patient outcomes 
which have been correlated with genetic test results, we will be able to learn the signifi-
cance of many kinds of findings. Uniformly structured genetic test results that use stand-
ard codes will enable the development and deployment of well-structured, informed, pa-
tient-specific, and genetic test specific education materials. The proper representation of 
genetic results will also allow development of professional publications and other online 
resources that can be delivered by the EHR to clinicians within the patient care work flow 
through integration with the infobutton standard [21,26]. Secondary use of the combina-
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tion of genetic, genomic, and clinical data as exemplified by the eMERGE project are 
also made possible by such integration [27]. 
Easy to read (clinician friendly) reports may improve patient care [28]. With 
structured and coded results, the receiving systems can customize the content and format 
of reports according to local preferences and the needs of different target audiences. For 
example, information that is most important to patient care such as results, clinical rele-
vance of the tests, and recommendations can be placed at a prominent location in the re-
port. Some laboratory technical information that is of less interest to the clinicians, such 
as number of cells analyzed, may be placed at a less prominent location in the report. In 
our LOINC panels, we created a LOINC code “recommended action,” and the LOINC 
answer list for this code includes three values: genetic counseling recommended, con-
firmatory testing recommended, additional testing recommended. This structured and 
coded list is not part of the reports currently reported by the laboratories; we introduced 
this code to the cytogenetics LOINC panels with the hope that it would help promote cli-
nician friendly reports.  
Challenges in Naming Genetics Test Orderable 
Test order names are a special problem in genetics testing in general and molecu-
lar cytogenetics in particular because different laboratories use different naming styles 
and different names for the same meaning. For example, they variously use the syndrome 
name of interest, the test methods, the target specimen, and/or the targeted genome in 
their names. This situation creates a problem for ordering clinicians because the actual 
testing varies from laboratory to laboratory and within a single laboratory over time. 
NCBI is working to develop a database that intends to capture the fine details of genetic 
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test procedures by laboratory to ameliorate this problem. We do not propose a set of 
standard names for genetic tests orders in this proposal; rather, we propose a way to con-
vey all of the relevant information about the test that was done and its results within the 
test report.  
The severity of the problem with test order names varies with the method type. 
The test order names for a conventional banding technique are relatively consistent across 
laboratories. For example, conventional karyotyping order names are usually based on 
specimen type, e.g., blood or amniotic fluid. Order names for FISH tests vary the most. 
Some laboratories ask the ordering providers to first choose Chromosome Analysis FISH-
Metaphase test on the test requisition form, and then provide a separate menu for choos-
ing syndromes and or probes of interest (e.g., Williams syndrome, Cri-du-chat syn-
drome), but do not ask the user to identify the particular genomic sequences of interest. 
Other laboratories use the syndrome name, the method, and the genetic variation of inter-
est, to name their tests (e.g., “Williams syndrome, 7q11.23 deletion, FISH” and “Cri-du-
chat syndrome, 5p15.2 deletion, FISH” are shown as two different test names) [29]. The 
first approach, which names a test by independently combining the important semantic 
parts at the time of test order, could be described as a post-coordinated approach, and the 
second strategy of combining the various parts into a single test name prior to ordering 
could be described as a pre-coordinated approach. For the reporting of FISH test results, 
we chose the post-coordinated approach, because it is simple and flexible and requires the 
fewest number of codes to express the essential nature of the test. A zero-to-many FISH 
Probe Panel reports all the FISH probes used in a FISH test.  
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Because arr testing targets the entire genome, the naming of arr test orders is less 
complicated than for FISH testing, and typically needs only the type of specimen pre-
coordinated with the arr platform (usually commercially purchased). The arr platforms do 
vary considerably by laboratory so our proposed reporting specification requires both the 
commercially obtained microarray platform and its version number to be recorded. 
One of the efforts of International Standard Cytogenomic Array Consortium 
(ISCA) is to develop recommendations for standards for the design, resolution and con-
tent of the cytogenomic arrays, and the design is intended to be platform and vendor neu-
tral [30]. And while the three laboratories we worked with happened to use the same arr 
platform, they have named their arr tests differently, e.g., “Genomic Microarray, U-Array 
Chip”, “Chromosomal Microarray, EmArray 60 K”, and “Array Comparative Genomic 
Hybridization (aCGH), Whole Genome, Constitutional” [29,31–32]. Without communi-
cation with the cytogenetics laboratories, clinicians and patients will not be able to de-
termine whether these tests produce comparable results based on the test names alone. 
We created a platform and vendor neutral LOINC code to represent the arr test, chromo-
some analysis microarray copy number change panel, and allow for the differences in 
platforms to be described within the result message. 
We encourage laboratories to employ the panel names we have proposed for or-
ganizing reports as order names where they apply, but they can also continue to use their 
local order names which will be included in OBR-4, Universal Service Identifier, for 
linking the report to the originating order, but continuing effort in the cytogenetics indus-
try to standardize cytogenomic array design and their naming will be critical in improv-
ing interoperability in ordering. 
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Limitations 
Our analysis of cytogenetic test names and results was not exhaustive. We re-
quested sample reports and imports from additional cytogenetics laboratories, and re-
ceived them from ARUP Laboratories, Emory Cytogenetics Laboratory, and Mayo Clinic 
Cytogenetics Laboratory. These are large and representative cytogenetics laboratories, 
which are active members of ISCA. We believe the information models and LOINC 
codes that we developed based on the sample result reports from these three laboratories 
are applicable to cytogenetic result reports from all other cytogenetic laboratories; eval-
uations including more institutions will be needed to substantiate this assertion.   
We have described how the LOINC codes for representing cytogenetics result re-
ports were developed. The sample result reports can be dissected based on the LOINC 
panel structures, and can then be transmitted through HL7 v2.x messages in a coded and 
structured way using these LOINC codes. 
Conclusions 
The proposed LOINC codes met our objective and will allow the use of well es-
tablished health informatics standards to exchange coded and structured cytogenetic test 
results between testing laboratories and ordering institutions. Use of standard structures 
and terminologies for cytogenetic results is critical for effective communication between 
testing laboratories and clinicians. This minimizes misinterpretation, leads to consistency, 
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Figure 3.1. Chromosome analysis G-banding panel 
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Figure 3.2. Chromosome analysis FISH panel 
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Figure 3.3. Chromosome analysis arr copy number change panel 
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Figure 3.4. Chromosome analysis master panel 
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Figure 3.5. Sample HL7 version 2 message for chromosome analysis G-banded 
test result 
  
OBR|1||PO-1000^ARUP|200291^Chromosome analysis chorionic villus sam-
pling^99ARU-ORDER-TEST-ID||20100702000000|20100702100909|||||| 
|201070201410||12345^Dr.Jones|||||| 20080703000000|||F||||||^Fetal demise|||||||||||||||||| 
62389-2^Chromosome analysis master panel^LN 




OBX|1|CWE|62358-7^ISCN band level^LN||LA14112-9^425^LN||||||F 
|201070201410|||||||||||ARUP Laboratories 
OBX|2|CWE|62359-5^Banding method^LN||LA14013-9^G-banding^LN||||||F 
|20080702100909||||||| ||||ARUP Laboratories 
OBX|3|NM|62361-1^Numer of cells counted^LN||20||||||F|201070201410 
|||||||||||ARUP Laboratories 
OBX|4|CWE|62366-0^Recommended action^LN||LA14020-4^Genetic counseling 
recommended^LN| |||||F|201070201410|||||||||||ARUP Laboratories 
OBX|5|FT|62385-0^Recommendation^LN||1. Genetic counseling. 2. Monitor sub-
sequent pregnancies with prenatal diagnosis||||||F|201070201410|||||||||||ARUP Laborato-
ries 
(… more OBXs could be placed here to represent other information in the G-
banding panel…) 
OBR|3||PO-1000-2^ARUP|62386-8^Chromosome analysis summary pan-
el^LN||20100702000000 |20100702100909|||||||201070201410||12345^Dr.Jones 
||||||201070201410|||F||||PO-1000^ARUP 
OBX|1|CWE|62357-9^Chromosome analysis result overall interpreta-
tion^LN||LA12748-2^Abnormal^LN||||||F|201070201410||||||||||ARUP Laboratories 
OBX|2|CWE|62356-1^Chromosome analysis result in ISCN expres-
sion^LN||47,XY^^2.16.840.1.113883.6.299^^^^2005||||||M|201070201410|||||||||||ARUP 
Laboratories 
OBX|3|CWE|48002-0^Genomic source class^LN||LA6683-3^Prenatal^LN||||||F| 
201070201410 |||||||||||ARUP Laboratories 
(… more OBXs could be placed here to represent other information in the sum-
mary panel…) 
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Figure 3.7. Sample HL7 version 2 message for chromosome analysis arr copy 
number change test result 
 OBR|1||PO-1001^ARUP|0040201^Genomic Microarray, U-Array Chip^99ARU-
ORDER-TEST-ID||20100702000000 |20100702100909|||||||201070201410 
||12345^Dr.Jones||||||20080703000000|||F||||||^Other developmental speech|||||||||||||||||| 
62389-2^Chromosome analysis master panel^LN | 
SPM|1|||^Peripheral blood|||||||||||||20100702100909 
OBR|2||PO-1001-1^ARUP|62377-7^Chromosome analysis arr copy number 
change panel^LN ||20100702000000|20100702100909|||||||201070201410| 
|12345^Dr.Jones||||||201070201410|||F|||| PO-1001^ARUP 
OBX|1|CWE|62374-4^Human reference sequence NCBI build 
id^LN||LA_X5^NCBI35^LN||||||F| 201070201410|||||||||||ARUP Laboratories 
OBX|2|CWE|62375-1^Arr platform^LN||^U-Array 
Cyto6000||||||F|201070201410|||||||||||ARUP Laboratories 
(… more OBXs could be placed here to represent other information in the arr 
panel…) 
OBR|3||PO-1001-2^ARUP|62386-8^Chromosome analysis summary pan-
el^LN||20100702000000 |20100702100909|||||||201070201410||12345^Dr.Jones|||||| 
201070201410|||F||||PO-1001^ARUP 
OBX|1|CWE|62357-9^^Chromosome analysis result overall interpretation^LN 
||LA12748-2^Abnormal^LN||||||F|201070201410|||||||||||ARUP Laboratories 
OBX|2|CWE|62356-1^Chromosome analysis result in ISCN expression^LN||arr 
cgh 1q21.1(143,612,538bp->145,024,147bp)x1^^2.16.840.1.113883.6.299^^^^2005| 
|||||F|201070201410 |||||||||||ARUP Laboratories 
OBX|3|CWE|48002-0^Genomic source class^LN||LA6683-2^Germline^LN|||||| 
F|201070201410|||||||||||ARUP Laboratories 
OBR|4||PO-1001-3^ARUP|62377-7^Chromosome copy number change pan-
el^LN||20100702000000 |20100702100909|||||||201070201410||12345^Dr.Jones| 
|||||201070201410|||F||||PO-1001-2^ARUP  
OBX|1|CWE|62378-5^Chromosome analysis copy number change type^LN|| 
LA14034-5^Deletion^LN||||||F|201070201410|||||||||||ARUP Laboratories 
(… more OBXs could be placed here to represent other information in the copy number 
change panel…) 
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     Specimen received 
 
Specimen type:         Peripheral Blood 
Reason for referral:   Other Developmental Speech Disorder  
Test performed:        GMA URRAY 
 
 
     …………………………………………………………………………………… 
     ABNORMAL MICROARRAY RESULT 
 
     Copy number change: 1q loss 
     Chromosome Bands involved:  1q21.1 
     Base pair coordinates:  143,612,538 – 145,024,147 
     Approximate Size: 1.4 Mb 
 
     ISCN nomenclature: arr cgh 1q21.1(143,612,538bp->145,024, 
     147bp)x1 (hg 17) 
     …………………………………………………………………………………… 
    Diagnostic impression: 
    Characterization of DNA from this patient was done using comparative genomic              
hybridization (CGH) microarray. Analysis using the U-array Cyto6000 array  
platform (Human Genome build: hg 17) indicated that there was a deletion  
on chromosome 1 (1.4 Mb deleted) involving 40 oligonucleotides within  
1q21.1, suggesting partial monosomy for this region. The deletion includes  
the GJA5 gene in addition to other genes. Deletion in this region have been  




   
1st OBR
OBR-3: (Filler Order Number) PO-1000 
^ARUP
OBR-4: (Universal Service Identifier) use 
LOINC panel code where apply, or use local 
code
OBR-50: (Parent Universal Service Identifier)                                                                   
Chromosome analysis master panel
OBR
OBR-3: PO-1001^ARUP












OBX-3: Chromosome analysis result 
overall interpretation
OBX
OBX-3: Chromosome analysis result in 
ISCN
OBR|1||PO-1000^ARUP|200291^Chromosome 
analysis chorionic villus sampling^99ARU-ORDER-
TEST-ID||20100702000000|20100702100909 
||||||| 201070201410||12345^Dr.Jones|||||| 






















OBX|2|CWE|62356-1^Chromosome analysis result 




Figure 3.9. Nested HL7 version 2 OBR/OBX segments with Cytogenetic LOINC codes 
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CHAPTER 5 
LOINC PANELS COUPLED WITH HL7 VERSION 2  
 
MESSAGING STANDARDS FOR TRANSMITTING 
 
CYTOGENETIC TEST RESULTS 
Personalized medicine is changing today’s healthcare; it will continue to revolu-
tionize future medicine. Genetic testing is a key component of personalized medicine. 
The Genetics Test Registry defines a genetic test as the analysis of DNA, RNA, chromo-
somes, proteins, or metabolites to detect genotypes, mutations, chromosomal changes, or 
levels of gene expression in a human sample [1]. Genetic testing can help physicians bet-
ter understand a patient’s genetic makeup resulting in more informed clinical decisions 
about prevention, diagnosis, and disease treatment for improved outcomes [2]. However, 
many physicians lack the knowledge required to take advantage of the advances brought 
by the growing scientific understanding of the links between genetics and the predisposi-
tion to diseases [3,4]. To take full advantage of information generated by genetic tests in 
daily patient care, we need to first integrate genetic and genomic data into Electronic 
Health Records (EHRs) in a consistent coded and structured format.  
Introduction 
EHRs can improve caregivers’ decisions and patients’ outcomes [5]; they are be-
lieved to be the catalyst that will allow for the systematic integration of genomic data 
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within an individual’s medical record [6]. One of the most significant benefits of EHRs is 
their ability to provide clinical decision support (CDS) and education at the point of care. 
The need for a robust health information technology infrastructure, which includes a CDS 
component, is critical to realize the promise of personalized medicine [7–9]. Kawamoto 
et al identified a list of required infrastructure components that must be met to provide 
CDS for enabling widespread and effective practice of personalized medicine [10]. 
Standardized data representation—both information models and terminologies—is a vital 
component among these prerequisites. These standardized detailed clinical models cou-
pled with standardized terminologies can be utilized with messaging standards, which is 
crucial to allow data flowing electronically from genetic testing laboratories to clinical 
institutions to be integrated with clinical data in a coded and structured format consistent-
ly.    
A detailed clinical model is a conceptual specification of the semantics of discrete 
structured clinical information [11]. The model defines data elements, attributes, relation-
ships, and constraints that are needed to unambiguously and consistently communicate a 
specific set of clinical data or knowledge. Detailed clinical models are fundamental to 
achieving semantic interoperability. Briefly, all detailed clinical models can be modeled 
under the basic name-value pair (also known as entity-attribute-value) paradigm for flex-
ible representation. The structure of a detailed clinical model will specify exactly how 
standard terminologies are to be used in the model. Each variable within a detailed clini-
cal model is bound to a formal data type to indicate whether it is coded, numeric, or other 
types of value.  
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Because detailed clinical models are abstract representations, they should be 
modeled with a disregard for what technology will be used. Several notable logical repre-
sentation formalisms have evolved over the years within the medical informatics com-
munity. openEHR Foundation has developed archetypes. Archetypes are described using 
Archetype Definition Language (ADL), which resembles a programming language with 
its own defined syntax [12]. Intermountain Healthcare has a long history of developing 
and implementing clinical information models. Information models at Intermountain 
were first represented using ASN.1 [13]. Intermountain Healthcare has since evolved its 
ASN.1 models and developed Clinical Element Models (CEMs) [14]. The second genera-
tion of models used Clinical Element Modeling Language (CEML), which is based on 
Extensible Markup Language (XML) to specify CEMs. The most recent version of CEMs 
is represented using the Constraint Definition Language (CDL), which is a context-free 
grammar developed by GE Healthcare. Health Level Seven (HL7) has taken the approach 
of defining HL7 templates, for example, entry-level templates for Clinical Document Ar-
chitecture (CDA). An HL7 template is a set of constraints on the HL7 Reference Infor-
mation Model (RIM) or constraints on a RIM derived model such as CDA; it is also ex-
pressed in XML. The Unified Modeling Language (UML) has also been used in creating 
clinical models for EHR systems such as VistA. Archetypes, CEMs, CDA templates, and 
UML are just a few examples of different formal syntaxes that can be used to represent 
clinical information models. Logical Observation Identifiers Names and Codes (LOINC) 
also has a well-developed model for defining data models for complex clinical infor-
mation; this is through the representation of variables, answer lists and collections that 
contain them [15].  
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Guided by the conceptual models, we have developed a set of LOINC terms for 
reporting constitutional cytogenetic test results. These LOINC panel codes are now avail-
able to the public as part of the official LOINC database release. One of the goals of 
LOINC is to facilitate interoperable exchange of results. We have coupled the cytogenet-
ic LOINC panels with HL7 version 2 results messages to transmit cytogenetic test results 
from genetic testing laboratories to receiving clinical institutions. The purpose is so that 
the cytogenetic results can then be embedded in the EHRs as coded and structured data. 
In this article, we describe the advantages of coupling the LOINC panel content to HL7 
V2.x messages, and why we think this approach could be a practical and efficient way for 
implementers to develop interfaces that utilize standard information models bound to 
standard terminologies.  This strategy could bring not only cytogenetic test results but 
other types of genetic and genomic data into EHRs.  
HL7 version 2.x (“x” could be any version within the version 2 family) messaging 
standards are the most widely implemented healthcare information standard in the world 
[16]. Over 95% of U.S. healthcare organizations use HL7 2.x. More than 35 countries 
have HL7 2.x implementations. HL7 2.5.1 is the Meaningful Use standard for submission 
of lab results to public health agencies that is published by the Office of the National Co-
ordinator (ONC) for Health Information Technology (HIT) [17]. LOINC is designed to 
provide universal codes for identifying observations sent in messages in data exchange 
standards like HL7 and Digital Imaging and Communication in Medicine (DICOM) [18]. 
Each LOINC term consists of a six-part structure: component (analyte), kind of property, 
time aspect (timing), system (sample), type of scale, and type of method. The concept of 
Background 
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panels has long existed in LOINC. Within LOINC, panels mean collections that have 
enumerated discrete contents. In recent years, LOINC has focused on development of 
panels to represent structured collections of observations [15]. Since LOINC’s first re-
lease in 1996, it has become the most widely adopted standard for laboratory test result 
names in the United States and internationally. LOINC is also the Meaningful Use vo-
cabulary standard for laboratory results [17].  
Realizing that gaps exist in traditional healthcare information standards for the 
genetic testing domain, LOINC has been extending its coverage for genetic testing, in-
cluding cytogenetic testing, in recent years [19,20]. Cytogenetic tests evaluate chromo-
somes from the nucleus of the cell for changes in number or structure. Cytogenetic test-
ing traditionally has been the first tier of genetic testing for a number of clinical situations 
such as assessment of a developmentally delayed child, evaluation of a cancerous tumor, 
or amniocentesis to detect chromosomal anomalies in a fetus [21]. A constitutional cyto-
genetic abnormality occurs in the germline, while a cancerous cytogenetic abnormality is 
an acquired (somatic) genetic change associated with a neoplastic process. Cytogenetic 
testing techniques have evolved over the years. The spectrum of tests spans from conven-
tional banding to molecular cytogenetics where techniques such as flurorescence in situ 
hybridization (FISH) and cytogenomic microarray (arr) are used routinely. Cytogenetic 
tests are now playing a more important role in routine patient care by providing the capa-
bility of detecting genome wide abnormalities at high resolution. It is essential to develop 
standard terminologies for representing cytogenetic test results, which will help clinicians 
to utilize these test results more effectively during their daily practice. 
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Different from other genetic tests, results of cytogenetic tests are reported using 
the International System for Human Cytogenetic Nomenclature (ISCN). ISCN was creat-
ed by the International Standing Committee on Human Cytogenetic Nomenclature, which 
has been a gold standard of describing cytogenetic and molecular cytogenetic findings in 
both clinical and research reports since 1960 [22]. ISCN provides a list of symbols and 
abbreviated terms in adjunct with a set of rules to annotate cytogenetic test outcomes: 
symbols such as p for short arm of chromosome, q for long arm of chromosome, del for 
deletion, ish for in situ hybridization, arr for microgenomic microarray, and plus sign (+) 
for gain. As the field of cytogenetics continues to include several molecular-based tech-
nologies, the latest revision of ISCN was published in 2009 to provide more up to date 
and accurate descriptions of the new technologies, e.g., a new chapter was added with 
nomenclature examples describing copy number detection due to rapid advancement in 
microarray technology [23]. ISCN is expected to continuously evolve as molecular tech-
nologies improve.  
 Each LOINC term corresponds to a single test result or panel. LOINC panels are 
collections that have enumerated discrete contents. The LOINC panel approach has been 
traditionally used for reporting laboratory collections such as a complete blood count 
(CBC) panel and a CHEM-7 panel. In recent years, LOINC panels have been successful-
ly applied to patient assessments for clinical LOINC, where a nested panel structure is 
used to represent the hierarchical nature of the survey instrument and questionnaires. 
Panel specific attributes and structured answer lists have been evolved to better support 
Methods 
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LOINC panels; LOINC panels are now a robust semantic data model through years of 
iterative refinement. [24]  
In the genetics and genomics domain, LOINC panels have also been successfully 
used to represent genetic variation results [19]. This has led to the first cross-country 
transmission of coded and structured genetic test results in 2009 [25]. We have followed 
a similar approach for genetic variation to represent cytogenetic test results. In the genetic 
variation model, detailed clinical models were developed first to clearly represent the se-
mantic relationships of data elements contained in result reports of sequencing and geno-
typing based genetic tests, where identified DNA sequence variants are located within a 
gene. These conceptual information models are structured collections of enumerated dis-
crete data elements contained in a genetic variation test result report, which are used to 
guide the creation of LOINC codes. Each data element slot in the information models has 
its corresponding LOINC code. The hierarchical relationship is represented using LOINC 
panel codes that are linked to an enumerated set of child elements. The child LOINC 
codes themselves can be panel codes, which enable multiple levels of nesting if needed. 
A LOINC panel code can have panel-specific attributes, e.g., it allows cardinality to be 
specified for each child element. If the data element has a coded result, the value of the 
result can be drawn from a LOINC answer list, or if applicable, from other standard ter-
minologies such as SNOMED-CT for diseases, and Human Gene Nomenclature Commit-
tee (HGNC) for gene symbols and identifiers.  
An HL7 2.x Unsolicited Point-In-Care Observation without Existing Order 
(ORU) message definition allows nesting of Observation Request segments (OBRs). 
Each OBR segment may contain one or many Observation Result segments (OBXs). 
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LOINC codes were initially designed to provide universal codes in messages, specifically 
to be used in OBR-4 Universal Service Identifier field and OBX-3 Observation Identifier 
field in an HL7 2.x message. The hierarchical LOINC panel structure fits nicely with the 
nested structure of OBR and OBX segments: the LOINC panel code will be sent in the 
OBR-3 field, the enumerated set of child LOINC terms that are contained in a panel will 
be sent in the OBX-5 fields as appropriate. If a LOINC panel contains nested panels, then 
nested OBRs will be used.  
The LOINC panel modeling approach used for developing the genetic variation 
model started from conceptual representation based on the business requirements and is 
not constrained by any particular representation formalism. It was developed though with 
a specific technology in mind, in this case, to transmit genetic variation results through 
HL7 2.x messages, the most widely implemented and most commonly used messaging 
method in the U.S. To help implementers, detailed instructions and guidance of how to 
use this LOINC-HL7 messaging framework for reporting genetic variations, where 
LOINC panels are tightly coupled with HL7 2.x messages, are described in the HL7 Ver-
sion 2 Implementation Guide: Clinical Genomics; Fully LOINC-Qualified Genetic Varia-
tion Model, Release 1 [19]. 
Applying the same LOINC panel approach to develop LOINC codes for cytoge-
netic test results worked nicely. We have created the LOINC panel, “Chromosome analy-
sis master panel in Blood or Tissue” (LOINC # 62389-2), as an overall parent. This mas-
ter panel contains three subpanels, which define the results of a G-Band, FISH and arr 
study, respectively. All cytogenetic test results are represented using ISCN notation, but 
Results 
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for tests that were done with different techniques, discrete data that were sent along with 
the result report varies, therefore, a different panel was created. The master panel for cy-
togenetic test results contains 65 LOINC codes, 7 of which are panel codes. We have re-
used the LOINC codes from the genetic variation model as much as possible. In this arti-
cle, we will not describe the cytogenetic LOINC panels in details, since the complete list 
of the cytogenetic panels and their enumerated LOINC terms can be obtained from the 
LOINC database. One can use the freely available RELM A tool from Regenstrief Insti-
tute or through the online search tool through the LOINC website to search and view the 
complete panel hierarchy [26].  
We have also developed the HL7 Version 2 Implementation Guide: Clinical Ge-
nomics; Fully LOINC-Qualified Cytogenetics Model, Release 1 [27]. This implementa-
tion guide was sponsored by the HL7 Clinical Genomics Workgroup, the same group that 
sponsored the genetic variation model. The implementation guide specifies in details how 
the LOINC panels for cytogenetics should be used with HL7 OBR and OBX segments 
with sample messages for illustrations. The implementation guide was balloted as an HL7 
informative document in the January 2012 HL7 ballot. Representatives that voted on the 
implementation guide came from government/non-profit organizations, pharmaceutical 
companies, health care provider organizations, and vendors.  
Genetic testing is increasingly relevant to mainstream medicine since the success-
ful completion of the Human Genome Project in April 2003. A genetic test can provide 
information on predispositions for a disease, presence of a disease, the risk of passing a 
disease onto offspring, and potential positive or adverse responses to therapeutic inter-
Discussion 
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ventions. More genetic tests are becoming available to clinicians. There are currently 
about 2,200 genetic tests available for clinical use and the number is continuing to grow 
rapidly. Patients are being exposed to greater amounts of genetic information routinely, 
and genetic/genomic data are becoming increasingly important for clinical decision mak-
ing. A study has shown that clinicians agree that knowing a patient’s genetic profile can 
influence treatment decision-making and importantly, can improve patient outcomes [28].  
The Personalized Healthcare Workgroup of the American Health Information 
Community (AHIC) has identified inclusion of relevant results from genetic tests in the 
EHR as immediate priorities for recommendation [29]. Government support for HIT has 
been strong in recent years, especially, under the American Recovery and Reinvestment 
Act of 2009 (ARRA). The Health Information Technology for Economic and Clinical 
Health Act (HITECH) offers funding for infrastructure and incentive payments to provid-
ers who adopt and use EHRs in a meaningful way. The Secretary’s Advisory Committee 
on Genetics, Health, and Society to the Health Information Technology Policy Commit-
tee had urged the committee to represent genetic and genomic information as fundamen-
tal information that need to be integrated into EHRs rather than as ad hoc specialty in-
formation. It specifically requested that the Meaningful Use objective to “incorporate lab 
tests into EHR” should explicitly reference genetic/genomic test results [30]. As the HIT 
infrastructure in the US improves and Meaningful Use of EHRs continues to expand in 
the near future, it is important to continue developing infrastructure components that are 
critical to successful and widespread clinical integration of genetic and genomic data, 
hence to promote the continued development of personalized medicine.  
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Advantages of the LOINC Panel Approach 
Broad use of EHRs with coded and structured data is essential for realizing the 
promise of personalized medicine. Demand for standardized representation of genetic test 
results will continue to rise. The LOINC panel approach offers several advantages in 
meeting the needs in this particular area.  
First, the LOINC panel approach uses a well-developed model for representing a 
collection of clinical observations. LOINC panels have proven to be robust, flexible, and 
sustainable; they are not only able to represent test results in the genetics domain as 
demonstrated by the genetic variation model and the cytogenetics model, but also in other 
domains such as representing survey instruments and questionnaires. The LOINC panel 
approach continues to be applied in exciting new areas, for example, the Phenotypes and 
eXposures (PhenX) project, which develops measures for genome-wide association and 
other types of studies [31]. LOINC panels are model driven; they provide the agility and 
flexibility that is crucial to support the rapidly evolving nature of the genetic testing field. 
As existing technologies evolve, new technologies emerge, and as new findings are dis-
covered and need to be included in the clinical reports, LOINC panels can be easily 
adapted to the changes and new additions. The LOINC panels we have created for the 
cytogenetic test results are currently limited to constitutional cytogenetic tests, but we 
believe we could extend these panels to cover the reporting needs for cancer cytogenetic 
tests. Array technology is rapidly being incorporated into cytogenetics and molecular ge-
netics laboratories; cytogenetics is increasingly expanding into cytogenomics. When we 
developed these LOINC panels, single-nucleotide polymorphism (SNP) microarrays were 
only used in a research setting but are now routinely used by many clinical laboratories. 
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Our panels are versatile enough to easily incorporate results from these platforms. This 
could be another exciting new test for us to cover in the near future by extending the 
LOINC cytogenetics panels. As the HL7 2.5.1 implementation guide for reporting cyto-
genetic tests reaches broader audiences and different stakeholders, we expect to continue 
refining these LOINC panels based on ballot feedback through the rigorous HL7 ballot 
reconciliation process.  
 Second, by design the natural coupling between LOINC panels and the HL7 2.x 
messages will allow EHR systems to leverage their existing infrastructure especially in 
the U.S. realm. We expect this will lead to rapid implementation and development for 
supporting new standardized and coded data structures for genetic test results where 
LOINC panels and HL7 v.2 messages are used. Both LOINC and HL7 v.2 messaging 
standards are widely implemented in the U.S.; Meaningful Use will only make them even 
more accessible to institutions and clinics. Collaborating with the Harvard Medical 
School – Partners Healthcare Center for Personalized Genetic Medicine, Intermountain 
Healthcare reported the first cross-country transmission of coded and structured genetic 
test results. This pilot implementation was based on the existing HIT infrastructure of In-
termountain Healthcare, and conforms to the HL7 2.5.1 implementation guide for genetic 
variation model. The same implementation strategy could easily be reused when Inter-
mountain Healthcare implements the cytogenetics model. The pilot implementation’s 
success has demonstrated that using the LOINC panel approach to represent genetic test 
results would require few changes by implementers, which is significant considering the 
high volume of genetic and genomic data that EHRs will be expecting to receive in the 
very near future. The price to consumers to sequence a complete human genome is pre-
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dicted to drop to $1000 in 2014[32], and experts believe that we may expect tens of mil-
lions of personal genomes to be sequenced worldwide by 2020 [33]. 
Third, the coupling between LOINC panels and HL7 2.x messages provides a 
mechanism that could potentially overcome some of the known weaknesses of HL7 2.x 
messages. HL7 2.x messages are known to have vague definitions of message structures 
and have built in a substantial amount of optionality, which has left room for a great deal 
of variability among implementations and has created difficulties for achieving true in-
teroperability. LOINC panels allow semantic relationships to be expressed unambiguous-
ly through the LOINC hierarchical structure, which includes cardinalities, data types, and 
answer lists. LOINC codes are created for each data element contained in a LOINC pan-
el. So LOINC panels are able to provide not only a standard structure for representing a 
collection of clinical observation, but also standard and widely accepted terminologies for 
data element names. Without standard terminologies, data models alone will not easily be 
shared across different systems. Using the LOINC panels to guide the construction of a 
HL7 2.x message creates synergy by combining the well-developed LOINC model for 
defining semantics and widely implemented HL7 2.x messages as the messaging vehicle.  
Fourth, LOINC panels as one form of physical representation can be transformed 
to other information modeling formalisms to meet different implementation technology 
requirements. The Implementation Guide for CDA Release 2 Genetic Testing Report uses 
LOINC codes for genetic variations and cytogenetics in defining its genetic variation and 
cytogenetics sections [34]. During the genetic variation model pilot implementation, In-
termountain Healthcare transformed the LOINC panels for genetic variations to ASN.1 
models and used the latter as storage models for storing genetic variation test results in 
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the Clinical Data Repository. In contrast with HL7 templates and CDA templates, 
LOINC panels use business names, which align more closely to the detailed clinical 
models. Creation of LOINC panels does not require the same kind of steep and long 
learning curve that implementers experienced in creation of HL7 and CDA templates. 
Domain subject experts could focus on accurately expressing the clinical concept and 
knowledge that they need to model to meet the business requirements and vet the LOINC 
panels, rather than having to learn and struggling with how to express them through com-
plex physical representation within specific modeling formalism limitations. This ad-
vantage could be important while we are trying to bridge the knowledge gap due to the 
lack of genetic and genomic knowledge among clinicians and most likely even more so 
among healthcare IT professionals in general. The HL7 Structured Document Workgroup 
has introduced the “greenCDA” technology that aims to simplify CDA creation and im-
plementation while maintaining the common basis required for semantic interoperability 
[35]. “greenCDA” uses simplified XML schemas and business names. Though the 
“greenCDA” technology is promising, it has potential issues as well. For example, it is 
currently still a very manual process and yet to be automated, widely accepted, imple-
mented, and tested. On the other hand, LOINC panels have been widely implemented and 
tested in many domains including genetic testing.    
Challenges  
We have encountered some challenges with the LOINC panel approach through 
our development of cytogenetics LOINC panels. We found it is sometimes challenging to 
determine when a LOINC term used in a panel should be reused in other panels and when 
a new LOINC term or panel should be created. When a LOINC term is used to represent 
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a data element within a panel, we need to evaluate it in the context of that panel to make a 
determination. When we create LOINC panels and their contained discrete LOINC codes, 
we might need to take into consideration that a particular term could be potentially reused 
by other panels, and therefore not to constrain its LOINC six-axis for a narrower use case 
only. For example, we did not constrain the method part of the LOINC term 62366-0, 
Recommendation:Imp:Pt:Patient:Doc, to Molgen (molecular genetics), so this term could 
be reused in other domains other than genetics. 
A LOINC term with a defined answer list may add more complexity to the shar-
ing and reuse of existing LOINC codes across different LOINC panels. LOINC allows 
answer lists to be declared as either normative or example. An answer list that is norma-
tive is meant to be comprehensive of all allowed values and adheres to a published stand-
ard, while an example answer list only displays some example answers to the question 
posed by the LOINC code. LOINC answer lists can contain enumerated values that are 
stored in the LOINC database, or the answer list can “point” to an external list of values 
drawn from another code system that is uniquely identified by an Object Identifier (OID). 
A LOINC code that may seem appropriate for reuse might have a different answer list 
with different meanings in the context of two different LOINC panels. It will be a contin-
uous and iterative effort for LOINC to address and harmonize these use cases. Interoper-
ability is a journey, and developing standardized information models coupled with stand-
ard terminologies—one of the most fundamental components of interoperability—is a 
journey itself. The LOINC Committee is continuously improving and iteratively refining 
its approach for developing LOINC panels.  
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Use of LOINC panels is just one form for representation of conceptual infor-
mation models. Different representation formalisms exist today, each with its own ad-
vantages and disadvantages. They have each been implemented differently, which in a 
way has become a significant barrier to interoperability itself. To solve this particular 
problem, the Clinical Information Modeling Initiative (CIMI), an international collabora-
tion, is attempting to provide a universally acceptable representation formalism for mod-
eling health information content [36]. It is our hope that models derived from universally 
vetted detailed clinical models bound to LOINC codes could be transformed into differ-
ent representation formalisms such as HL7, CDA templates, and archetypes and be im-
plemented in different implementation technology environments.  
Clinical Decision Support 
Standard representation of genetic and genomic data is a vital component of the 
CDS infrastructure for personalized medicine. Genetic and genomic discovery is taking 
place at a breathtaking pace since the completion of the Human Genome project, and it 
has added a new dimension to the idea that “clinicians need help” that triggered the be-
ginning of medical informatics decades ago. Clinicians will be unable to keep track of the 
genetic and genomic information relevant to patient care, especially trying to interpret it 
in the context of an individual patient. CDS rules for genetic and genomic information 
that are incorporated in EHRs have the potential to prevent harm to patients due to misin-
terpretation of genetic test results and help clinicians provide adequate and appropriate 
counseling. To maximize such potential, genetic and genomic data must be integrated 
into EHRs as coded and structured data represented using accepted standards. Decision 
support must be delivered as part of the clinician’s decision-making process at the appro-
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priate time, and EHRs must be flexible to meet the rapidly growing and evolving nature 
of genetic and genomic information and the field of genetic testing.  
Integration of coded and structured genetic and genomic data within EHRs has  
also made it possible for the secondary use of the combination of genetic, genomic, and 
clinical data. The Electronic Medical Records and Genomics (eMERGE) Network is a 
pilot project that is funded by the National Human Genome Research Institute and the 
National Institute of General Medical Sciences [37]. eMERGE participants have been 
exploring whether the use of EHRs could support genome-wide association analysis.   
LOINC panels provide structured semantic representation for a list of discrete clini-
cal data elements, as well as binding to widely accepted standard terminologies for nam-
ing the collections and the individual data elements they contain. LOINC panels also pro-
vide the agility and flexibility that are crucial to meet the integration requirements of the 
dynamic and rapidly growing field of genetic testing. Coupled with HL7 2.x messages, 
the most widely implemented HIT standard in the world, LOINC panels can lead to rapid 
implementation by leveraging existing EHR infrastructures especially in the U.S. realm.  
Conclusions 
LOINC panels were previously used in the development of LOINC terms for genet-
ic variation test results. We have successfully applied the same LOINC panel approach to 
develop LOINC terms for cytogenetic test results, which has further proven that LOINC 
panels can be an effective modeling formalism for representing genetic tests results in the 
general case. Implementers can also potentially transform LOINC panels into other mod-
eling formats to fit different implementation technology requirements.   
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CHAPTER 6 
DISCUSSION 
Genetic and genomic information needs to be integrated into EHRs in a coded and 
structured format to be clinically meaningful and to enable clinical decision support at the 
point of care. However, today’s EHRs are not ready for genomic medicine [1]. Lack of 
standardized data representation and terminology standards are among major barriers for 
interoperable integration of genetic and genomic test information. Among different types 
of genetic tests, cytogenetics is often the first tier of genetic testing for assessment of a 
child with multiple congenital abnormalities and/or developmental delay, prenatal detec-
tion of chromosome anomalies, detection of mosaicism, or evaluation of oncological 
specimens [2]. Currently, most genetic test results, including cytogenetic test findings, 
are stored in long textual reports. These reports are then transmitted from the testing la-
boratories to the clinical institutions and stored as narrative texts.  
Summary 
During this study, we first evaluated LOINC, the de facto terminology standard 
for representing laboratory test names and results. We found that a gap existed in LOINC 
to support the integration of cytogenetic test results into EHRs. There were only a few 
LOINC terms for cytogenetics and they do not match well with how cytogenetic tests are 
reported. To fill this gap, we have taken the LOINC panel approach and developed 
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LOINC panels and terms for representing constitutional cytogenetic test findings by ana-
lyzing sample clinical reports.  
We contacted five large cytogenetics laboratories in the U.S.: ARUP Laborato-
ries, Mayo Clinic Cytogenetics Laboratory, Emory Cytogenetics Laboratory, Genzyme 
Genetics (now Integrated Genetics, LabCorp Specialty Testing Group), and Signature 
Genomics. Three of the five laboratories were able to send us their sample reports. We 
received 19 sample reports from ARUP, 12 from Emory, and 16 from Mayo Clinic. We 
created information models based on the key data elements extracted from the ARUP re-
sult reports. The information models were able to cover the key data elements extracted 
from the Mayo result reports. But the Emory result reports for cytogenomic microarray 
analysis contained a “microarray platform version number,” which did not exist in both 
ARUP and Mayo reports. We believe this new data element is important and should be 
included in our information models. Based on the information models, we created a mas-
ter panel to contain three LOINC subpanels; each of the three subpanels held the structure 
for chromosome analysis results that uses a different technique: G-banding, FISH, and 
cytogenomic microarray.  
Our research goal was to cover the most important data elements contained in the 
reports. We believe the list of key data elements that we extracted from these three cyto-
genetic laboratories covered about 80% of the data variable names in the cytogenetic test 
result report, and the LOINC panels we created are able to represent 100% of these key 
data elements. We then created an HL7 implementation guide using the LOINC panel 
codes. The strategy for using LOINC panels to define the contents of data exchange mes-
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sages represents a pattern that can be used for other types of genetic results as well as for 
the representation of other non-genetic complex data.  
The Secretary’s Advisory Committee on Genetics, Health, and Society stated to 
the Health Information Technology Policy Committee that “Clinical decision support for 
genetic/genomic information in the context of the EHR has the power to prevent potential 
harms to patients due to misinterpretation of genetic test results and help primary care 
physicians provide adequate and appropriate counseling. Clinical decision support tools, 
made available at appropriate times, will enhance patient care. This goal cannot be met 
unless genetic/genomic information is available in the EHR.” [3].  By focusing on devel-
oping standardized data representation for cytogenetic test result reports, this study has 
helped to overcome one of the main barriers for integrating genetic/genomic information 
into EHRs and enabling clinical decision support.   
Contribution to Biomedical Informatics 
The results of this study filled the gap that previously existed: there were no 
standard information models and no standard terminologies for representing constitution-
al cytogenetic test results. LOINC is the de facto terminology standard for laboratory re-
sults. LOINC panels and LOINC terms for constitutional cytogenetic test results are now 
contained in the LOINC database openly accessible by the public. 
This study further supported that the use of the LOINC panel approach coupled 
with HL7 V2 messaging standards could be a practical and efficient way to develop inter-
faces that utilize standard information models and standard terminologies; an HL7 V2 
implementation guide for cytogenetic test results was balloted as a result. This generic 
LOINC panel approach can be applied not only to cytogenetic test results, but potentially 
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also to other types of genetic test results. It takes advantages of existing infrastructure in 
almost all EHR systems in the current US market, which will certainly help to speed up 
the adoption and implementation process, and thus, help to make structured and coded 
genetic/genomic information available in the EHR in the very near future.   
Personalized medicine is experiencing a rapid growth following the completion of 
the human genome project. The consumer price to sequence a complete human genome is 
predicted to drop to $1000 in 2014 [4]. Experts also believe that we may expect tens of 
millions of personal genomes to be sequenced worldwide by 2020 [5]. This is an exciting 
time for the biomedical informatics community to build foundations necessary to bridge 
the chasm between the bench and the bedside to take full advantage of the promise of 
personalized medicine. Ample opportunities exist to expand and refine our study. 
Future Directions 
This study focused on constitutional cytogenetic test results. We intend to analyze 
cancer cytogenetic test reports to expand our information models and LOINC panels.  As 
new technologies, such as single-nucleotide polymorphism (SNP) arrays, now allow for 
clinical applications, we plan to expand the LOINC coverage to include SNP arrays. 
SNPs are DNA sequence variations in which a single nucleotide in the sequence of the 
genome differs between individuals or between paired chromosomes in an individual [6]. 
As we expand the content to cover SNP arrays and cancer cytogenetic test results, we will 
continue to ballot the implementation guide through HL7 in the future under the support 
of HL7 Clinical Genomics Workgroup. However, for the current cytogenetics HL7 im-
plementation guide [7], we feel that it is more important at this stage to start actively ex-
ploring the opportunities of creating a pilot real-world implementation. Real-world im-
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plementations prove the standard is implementable and support real-world conditions. A 
pilot real-world implementation will provide us valuable information to further refine and 
improve the standard.  
Cytogenetic test results are expressed using ISCN notations. Currently, though we 
have assigned this data element a coded data type, we expect the result will be stored as a 
string initially. A parser that can parse the ISCN expression based on the latest 2009 ver-
sion of the nomenclature could potentially be an extremely valuable tool. It can dissect 
the cytogenetic findings based on the nomenclature and store the complete finding as dis-
crete structured results. During this study, we did not focus on structuring the narrative 
texts within the recommendation and diagnostic impression sections. We believe that the 
best approach to interoperability is taking incremental steps; therefore, our goal in this 
study was to get the key information of constitutional cytogenetic test results into EHRs 
as coded and structured format first. We could apply natural language processing in the 
future to extract key information from narrative texts as the need arises.  
Once coded and structured cytogenetic test results are integrated into the EHRs, it 
will lead to many exciting opportunities. We hope to study how to best display the 
cytogenetics clinical report in a clinician friendly format. We also hope to use alerts to 
bring available best practice treatment guidelines of syndromes to the attention of clini-
cians, and to use infobutton technology to present the most relevant genetics information 
to the clinicians that are tailored based on the cytogenetic test results of an individual pa-
tient. We would also like to conduct secondary use studies on the integrated cytogenetic 
and phenotypic data.   
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Unlike basic clinical chemistry tests and simple imaging studies where results 
represent a clinical picture at a single point in time, genetic tests results on tissues derived 
from the germline, such as constitutional cytogenetic tests, are valid for the lifetime of the 
individual, and perhaps longer as genetic data may have relevance for the individual’s 
offspring and other relatives [8]. However, current interpretation of genetic test findings 
for complex conditions may change over the course of an individual’s lifetime as a result 
of new research findings or advances in technology to interpret extensive sets of genomic 
data. We plan to explore the strategies of how to access an up-to-date genetic knowledge 
base, how to trigger and prompt for reinterpretation of the original test results (when rel-
evant new knowledge emerges or updates to the knowledge base have been made that 
require previous interpretations to be revisited) and how to notify clinicians and patients 
in an efficient and meaningful way. 
Finally, we expect to expand beyond the cytogenetic testing domain in the future. 
It is now time to start bridging the efforts of both the bioinformatics and medical infor-
matics worlds to integrate genetic and genomic information with EHRs. It will be im-
portant for us to work with the genetic experts and clinicians to understand the degree of 
complexity we need to bring genetic and genomic data into EHRs to be the most effec-
tive. As the genetic and genomic information flow from the laboratory bench to the bed 
side, different users may have different requirements regarding the level of complexity 
they would like to receive while maintaining data traceability during the entire data flow. 
It will also be important for us to leverage existing standards, tools, and expertise from 
the bioinformatics and medical informatics communities to provide best patient care. For 
example, bioinformatics researchers have started the Sequence Ontology (SO) project for 
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the purpose of standardizing genomic annotation. Sequence ontology is a structured con-
trolled vocabulary for the parts of a genomic annotation [9]. The Genome Variation For-
mat (GVF) is a computable standard variation file format for human genome sequences 
that uses the sequence ontology as descriptive terms [10]. We hope to work with the SO 
and GVF experts to see how we could use standard terminologies such as LOINC and 
HL7 messaging standards to help transmit variant files with EHR suitable information 
from the testing laboratories and embedding them in the EHRs, and improve the existing 
HL7 genetic variation implementation guide.  
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APPENDIX 
 LOINC CYTOGENETICS PANEL HIERARCHY 
 
 LOINC# LOINC Name Cardi-nality 
Data 
Type 
  62389-2   Chromosome analysis master panel in Blood or Tis-sue    
       62386-8   Chromosome analysis summary panel in Blood or Tissue by Molecular genetics method 1..1   
            62356-1   Chromosome analysis result in ISCN expression in Blood or Tissue by Molecular genetics method 1..1   
  
          62357-9   Chromosome analysis overall interpretation [inter-
pretation] in Blood or Tissue Qualitative by Molecu-
lar genetics method 
1..1   
            48002-0   Genomic source class [Type] in Blood or Tissue by Molecular genetics method 1..1 CWE  
            51967-8   Genetic disease assessed [Identifier] in Blood or Tis-sue by Molecular genetics method 0..n CWE  
            51969-4   Genetic analysis summary report in Blood or Tissue Document by Molecular genetics method 0..1 FT  
       62355-3   Chromosome analysis panel in Blood or Tissue by Banding    
            62386-8   Chromosome analysis summary panel in Blood or Tissue by Molecular genetics method 1..1   
                 62356-1   Chromosome analysis result in ISCN expression in Blood or Tissue by Molecular genetics method 1..1   
  
               62357-9   Chromosome analysis overall interpretation [inter-
pretation] in Blood or Tissue Qualitative by Molecu-
lar genetics method 
1..1   
                 48002-0   Genomic source class [Type] in Blood or Tissue by Molecular genetics method 1..1 CWE  
                 51967-8   Genetic disease assessed [Identifier] in Blood or Tis-sue by Molecular genetics method 0..n CWE  
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                 51969-4   Genetic analysis summary report in Blood or Tissue Document by Molecular genetics method 0..1 FT  
            62358-7   ISCN band level [#] in Blood or Tissue Qualitative by Molecular genetics method 1..1   
            62359-5   Chromosome banding method [Type] in Blood or Tissue by Molecular genetics method 1..1   
            62360-3   Cells analyzed [#] in Blood or Tissue by Molecular genetics method 0..1   
            62361-1   Cells counted [#] in Blood or Tissue by Molecular genetics method 0..1   
            55199-4   Cells karyotyped.total [#] in Blood or Tissue 0..1   
            62362-9   Colonies counted [#] in Blood or Tissue by Molecu-lar genetics method 0..1   
            62363-7   Mosaicism detected in Blood or Tissue by Molecular genetics method 0..1   
            62364-5   Test performance information in Unspecified speci-men Narrative 0..1   
            62365-2   Diagnostic impression [interpretation] in Unspecified specimen by Molecular genetics method Narrative 0..1   
            62385-0   Recommendation [interpretation] Document 0..1   
            62366-0   Recommended action [Identifier] 0..n   
       62367-8   Chromosome analysis panel in Blood or Tissue by Fluorescent in situ hybridization (FISH)    
            62386-8   Chromosome analysis summary panel in Blood or Tissue by Molecular genetics method 1..1   
                 62356-1   Chromosome analysis result in ISCN expression in Blood or Tissue by Molecular genetics method 1..1   
  
               62357-9   Chromosome analysis overall interpretation [inter-
pretation] in Blood or Tissue Qualitative by Molecu-
lar genetics method 
1..1   
                 48002-0   Genomic source class [Type] in Blood or Tissue by Molecular genetics method 1..1 CWE  
                 51967-8   Genetic disease assessed [Identifier] in Blood or Tis-sue by Molecular genetics method 0..n CWE  
                 51969-4   Genetic analysis summary report in Blood or Tissue Document by Molecular genetics method 0..1 FT  
            62368-6   Cell phase [Type] in Blood or Tissue by Molecular genetics method 0..1   
            62369-4   FISH probe name panel in Blood or Tissue by Mo-lecular genetics method 0..n   
                 62370-2   FISH probe gene name [Identifier] in Blood or Tis- 0..1   
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sue by Molecular genetics method 
                 62371-0   FISH probe locus [Identifier] in Blood or Tissue by Molecular genetics method 0..1   
                 62372-8   FISH probe vendor [Identifier] in Blood or Tissue by Molecular genetics method 0..1   
            62360-3   Cells analyzed [#] in Blood or Tissue by Molecular genetics method 0..1   
            62364-5   Test performance information in Unspecified speci-men Narrative 0..1   
            62365-2   Diagnostic impression [interpretation] in Unspecified specimen by Molecular genetics method Narrative 0..1   
            62385-0   Recommendation [interpretation] Document 0..1   
            62366-0   Recommended action [Identifier] 0..n   
       62343-9   Chromosome analysis microarray copy number change panel in Blood or Tissue by arrCGH    
            62386-8   Chromosome analysis summary panel in Blood or Tissue by Molecular genetics method 1..1   
                 62356-1   Chromosome analysis result in ISCN expression in Blood or Tissue by Molecular genetics method 1..1   
  
               62357-9   Chromosome analysis overall interpretation [inter-
pretation] in Blood or Tissue Qualitative by Molecu-
lar genetics method 
1..1   
                 48002-0   Genomic source class [Type] in Blood or Tissue by Molecular genetics method 1..1 CWE  
                 51967-8   Genetic disease assessed [Identifier] in Blood or Tis-sue by Molecular genetics method 0..n CWE  
                 51969-4   Genetic analysis summary report in Blood or Tissue Document by Molecular genetics method 0..1 FT  
            62373-6   Human reference assembly release, UCSC version [Identifier] in Blood or Tissue 0..1   
            62374-4   Human reference sequence assembly release number in Blood or Tissue by Molecular genetics method 1..1   
            62375-1   Microarray platform [Identifier] in Blood or Tissue by Molecular genetics method Narrative 1..1   
            62376-9   Microarray platform version number in Blood or Tis-sue by Molecular genetics method Narrative 1..1   
            62377-7   Chromosome copy number change panel in Blood or Tissue by Molecular genetics method 0..n   
                 62378-5   Chromosome copy number change [Type] in Blood or Tissue by Molecular genetics method 0..1   
                 62379-3   Chromosome band involved start in Blood or Tissue 0..1   
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by Molecular genetics method 
                 62380-1   Chromosome band involved end in Blood or Tissue by Molecular genetics method 0..1   
                 62381-9   Base pair start coordinate [#] in Blood or Tissue by Molecular genetics method 0..1   
                 62382-7   Base pair end coordinate [#] in Blood or Tissue by Molecular genetics method 0..1   
                 62383-5   Flanking normal region before start in Blood or Tis-sue by Molecular genetics method 0..1   
                 62384-3   Flanking normal region after end in Blood or Tissue by Molecular genetics method 0..1   
            62364-5   Test performance information in Unspecified speci-men Narrative 0..1   
            62365-2   Diagnostic impression [interpretation] in Unspecified specimen by Molecular genetics method Narrative 0..1   
            62385-0   Recommendation [interpretation] Document 0..1   
            62366-0   Recommended action [Identifier] 0..n   
 
 
